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Abstract
AGING EXACERBATES NEUTROPHIL PATHOGENICITY IN
ISCHEMIC STROKE

Meaghan Anne Roy-O’Reilly, M.S.

Advisory Professor: Louise McCullough, MD/PhD

Ischemic stroke is a major cause of disability and mortality worldwide. As
most patients cannot receive the currently approved therapies for ischemic
stroke, novel treatments are critically needed. Cerebral ischemia causes
irreversible tissue damage, referred to as the “tissue core”, which is surrounded
by a salvageable penumbral region. Excitotoxicity, oxidative stress and
inflammation can further damage this “tissue-at-risk”, resulting in even greater
functional loss and poorer injury outcomes.
Aging represents the single strongest risk factor for high mortality and
poor outcome after stroke in patients. This phenotype is also seen in animal
models, with aged mice experiencing higher mortality and poorer recovery than
their young counterparts. Our lab has recently shown that bone marrow
transplantation from young mice into aged mice improves functional outcome
after ischemic stroke, whereas aged bone marrow transplantation exacerbates
secondary brain hemorrhage in young mice. However, the identity of the
deleterious factor present in aged bone marrow remains unknown.
viii

Bone marrow is the main site of neutrophil differentiation, maturation and
storage. Neutrophils, innate immune cells with a rich arsenal of anti-bacterial
functions, traffic to the brain in large numbers following ischemic stroke. Age has
previously been reported to impair neutrophil protective functions (phagocytosis,
directed chemotaxis) and exacerbate neutrophil-driven inflammation (increased
reactive oxygen species generation, impaired neutrophil clearance). However,
there are currently no published studies on the effects of age on neutrophil
function and neutrophil-associated brain tissue damage after stroke.
Neutrophils are believed to exacerbate brain tissue injury in ischemic
stroke via the release of degradative enzymes and reactive species, leading to
blood-brain-barrier breakdown, secondary tissue hemorrhage and direct tissue
damage. In light of this data, neutrophil-mediated damage has gained
significantly interest as a potential therapeutic target in ischemic stroke.
Despite success in animal models, clinical trials of anti-neutrophil
therapies for ischemic stroke have been unsuccessful, due in part to the limited
specificity of available treatments and the tendency to test therapeutics in young
animals only. We believe this lack of specificity and the failure to include aged
animals in pre-clinical studies may have obscured the true contribution of
neutrophils to stroke pathology. In recent years, administration of the monoclonal
antibody anti-Ly6G has been found to specifically and robustly deplete
neutrophils in mice. Encouragingly, our early work confirmed that post-stroke
anti-Ly6G treatment results in a transient decrease in circulating neutrophils,
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making it a promising tool for testing the role of neutrophils in acute ischemic
stroke pathology.
In this dissertation, I hypothesized that age enhances the proinflammatory functions of neutrophils after ischemic stroke, directly contributing
to the poorer outcomes seen in aged animals. I tested this hypothesis by (1)
examining the effects of age on neutrophil inflammatory phenotype in vivo and ex
vivo, and (2) directly assessing whether neutrophil depletion had a differential
treatment effect in young vs. aged animals following ischemic stroke.
These studies not only examine the utility of post-stroke neutrophil
depletion therapy in young and aged animals, but also provide new insight into
the changing function of injury-induced inflammation throughout the lifespan. In
addition, we demonstrate that neutrophils from aged animals exhibit altered
behaviors, including an impaired clearance phenotype, greater sensitivity to
inflammatory stimulus and a higher capability for reactive species generation.
In this body of work, I have (1) examined neutrophil-activating cytokine
levels and neutrophil-associated gene pathways in human stroke patients, (2)
advanced scientific knowledge regarding the influence of age on neutrophil
function and neutrophil-related damage after ischemic stroke, (3) and improved
clinical translatability by testing the utility of post-stroke neutrophil depletion in
both young and aged animals.
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Chapter I
Introduction

1

1.1 The Heavy Burden of Stroke in Society
Stroke is the 2nd leading cause of death worldwide, affecting more than 15
million people annually.1 Stroke is responsible for 1 in 20 deaths in the United
States, with particularly high mortality seen in a region of the southeastern United
States known as the “stroke belt”.2 This region, which includes parts of eastern
Texas, experiences 30% higher stroke mortality than the rest of the nation.3 The
incidence of stroke around the world is tightly correlated with the incidence of
several stroke risk factors, including hypertension, hyperlipidemia, diabetes
mellitus, cigarette smoking, atrial fibrillation and cardiovascular disease.2
Patients who survive their initial stroke often experience permanent and
profound morbidity, as the brain is critically important to all human functions and
has limited ability to regenerate. Stroke often leaves patients with extensive, lifealtering dysfunctions, including weakness, paralysis, loss of speech,
incontinence, cognitive dysfunction, emotional lability and pain.4 Stroke also
places a heavy burden on the families of stroke patients, with stroke caregivers
reporting high levels of stress and depression.5
Due to its high incidence and extensive sequelae, stroke now represents
the leading cause of disability in the United States.1 By 2030, another 3.4 million
adults in the US will experience a stroke, increasing stroke prevalence by more
than 20%.6 The overall cost of caring for these stroke patients is projected to
reach upwards of $183 million dollars, driven largely by longer life expectancies
and a concomittant increase in our aged population.6
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1.2 Ischemic Stroke Pathophysiology & Current Treatments
A stroke occurs when blood flow to the brain is compromised. Bleeding
into the brain results in a hemorrhagic stroke, whereas ischemic strokes result
from the loss or blockage of blood flow within the vessels supplying the brain.2
This work will focus on ischemic strokes, which account for approximately 87% of
all strokes.2
Despite the high prevalence of ischemic stroke, there are currently only
two approved treatment options: (1) mechanical clot removal or (2)
pharmacological clot dissolution with tissue plasminogen activator (t-PA).
Unfortunately, clot removal procedures require fast access to high-level
endovascular care within six hours of stroke onset, which is not a reality for the
vast majority of stroke patients. Although pharmacologic t-PA therapy is more
widely available than mechanical intervention, t-PA can only be utilized in large
vessel ischemic stroke. However, the treatment window of t-PA and mechanical
retrieval is narrow (3-4.5 hours and 6 hours after symptom onset, respectively).7
Due to this brief treatment window, the vast majority of ischemic stroke patients
(>90%) do not receive t-PA or interventional surgery, leaving them with no viable
interventions in the acute setting.
Although many effective candidates have been identified in pre-clinical
studies, all prospective treatments have failed to provide significant clinical
improvement in stroke patients in Phase III clinical trials.8 If we are to reduce
stroke mortality and improve quality-of-life in stroke survivors, novel therapeutic
targets with significant translational potential are critically needed.
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To design effective clinical targets for stroke treatment, it is important to
understand the underlying pathophysiology of cerebral ischemia. Ischemic stroke
results in a permanent core brain injury, defined as tissue where cerebral blood
flow has been reduced to <20% of baseline. As neurons are exquisitely sensitive
to ischemia, cell death occurs rapidly at the core of the ischemic brain due to
acute energy failure, resulting in ionic disequilibrium, mitochondrial dysfunction
and breakdown of cellular components.9
Although the tissue core is thought to be irreversibly damaged within
minutes of stroke onset, the area surrounding the core region experiences an
intermediate reduction in cerebral blood flow reduction.10 This territory is known
as the ischemic penumbra, characterized by regions of dysfunctional cells that
may recover once blood flow has been restored.11
Both approved therapies for ischemic stroke (t-PA and clot retrieval) are
targeted towards recanalization, which removes the vessel blockage and allows
the return of blood carrying oxygen and glucose to the injured tissue.12 Although
these interventions can offer significant benefits to patients who arrive quickly to
skilled medical facilities, their narrow treatment window reflects their primary
method of action – reducing the severity of the primary ischemic injury.
Unfortunately, even when blood flow is restored via interventional therapy
or natural recanalization, the compromised tissue of the penumbra remains
endangered due to a wide array of secondary damage pathways initiated during
the primary injury.9 As this secondary damage takes place over a longer period
of time (hours to weeks) compared to the primary ischemic insult (minutes to
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hours), it is believed that therapies targeting secondary damage may have wider
therapeutic windows. In particular, excitatory neurotoxicity and inflammation have
been extensively studied as promising targets for ischemic stroke treatment.13, 14
Excitatory neurotoxicity is caused by a massive release of glutamate from
dying and damaged neurons, resulting in the widespread activation of neuronal
receptors that eventually results in profound cellular dysfunction and apoptosis.11
Experimental studies have found that targeting these excitatory neuronal
pathways, known as neuroprotection, can reduce cell death and improve
outcome after injury. Particularly well studied are N-methyl-D-aspartate (NMDA)
receptors, which have been shown to mediate glutamate-induced cell death.15, 16
Preclinical studies found that NMDA receptor blockade was highly
neuroprotective after stroke in young mice.17 Yet despite success in animal
models, all clinical trials of NMDA antagonists for ischemic stroke have failed,
with one study reporting a trend towards potential neurotoxic effects of the
treatment after stroke.18-22 Subsequent work in experimental models found that
NMDA antagonism after cerebral ischemia induces neuronal apoptosis and
suppresses brain tissue regeneration, or neurogenesis, which is critical for the
restoration function after ischemic stroke.23 This is due to the fact that, despite its
harmful role during injury, the beneficial role of NMDA receptor signaling in
normal neuronal physiology is integral to the healthy brain.
These results, and other failed trials of “neuroprotective” agents targeting
components of normal neuronal physiology indicate that these strategies are
largely ineffective and potentially unsafe for clinical populations.20 In light of this,
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we believe that targeting of other secondary injury mechanisms that do not
directly affect neurons (such as post-stroke inflammation) may result in greater
translational success.

1.3 Ischemic Stroke-Induced Inflammation
Inflammation after stroke is caused by several factors, including (1)
cellular activation and release of pro-inflammatory molecules from glial cells,
endothelium and neurons, and (2) activation and recruitment of circulating
peripheral immune cells.9 Following stroke onset, an array of danger associated
molecular patterns (DAMPs) and inflammatory cytokines are released from dead
and dying cells.9 Microglia, the innate immune cells of the brain, are activated
and release cytokines and chemokines, potentiating both the central and
peripheral inflammatory response.24 Inflammatory mediators generated in the
brain gain access to the periphery via the (1) cerebrospinal fluid outflow tracts,
(2) the systemic circulation via a disrupted blood brain barrier and (3) the
glymphatics, a perivascular system for lymph circulation in the brain.9 In concert,
these brain-derived DAMPS, cytokines and chemokines initiate the mass
activation and recruitment of peripheral immune cells into the injured brain.25
The earliest peripheral immune responders are neutrophils, followed
closely by monocytes/macrophages.4 In later injury stages, the body mounts an
adaptive immune response characterized by the activation and infiltration of
lymphocytes.26 Pre-clinical studies have shown that the peripheral immune
response can affect ischemic stroke outcome.8, 9 In addition, immune activation
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and leukocytosis independent of infection (increased white blood cells in
circulation) after stroke is predictive of poor outcome in patients, including higher
mortality, poorer functional recovery and extended hospital stays.8, 27, 28 In
particular, studies have found particularly robust associations between increased
circulating neutrophil counts, higher neutrophil gene expression, and poor
outcome after ischemic stroke.8, 28, 29

1.4 Neutrophil Biology
Human blood is rich in neutrophils, which make up approximately 60% of
our normal circulating immune cells. As neutrophils are typically very short-lived,
new neutrophils are constantly produced in the bone marrow during a process
known as granulopoiesis. Granulopoesis occurs on a massive scale, as humans
are estimated to generated approximately 1011 new neutrophils every day, with
even greater production under conditions of injury or infection.30 The
development of all blood cell lineages begins with hematopoietic stem cells
(HSC). Based on the levels of survival and differentiation factors (such as GCSF, discussed below), HSC can give rise to common myeloid progenitor (CMP)
or common lymphoid progenitor (CLP) cells.31 CMP cells then further differentiate
into monocyte erythrocyte precursor (MEP) or granulocyte monocyte progenitor
(GMP) cells, followed by GMP differentiation towards either a
monocyte/macrophage (monoblast) or granulocyte (myeloblast) lineage.
Granulopoiesis begins with myeloblasts, which are capable of differentiating into
the three types of granulocytes: neutrophils, eosinophils or basophils. Cells then
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pass through the promyelocyte, myelocyte and metamyelocyte stages, becoming
fully committed to the neutrophil lineage during the myelocyte-metamyelocyte
transition.32
Granulocyte colony-stimulating factor (G-CSF) is a major regulator of
neutrophil production from progenitor cells, where it stimulates hematopoeitic
progenitor proliferation and upregulates the expression of neutrophil-biasing
transcription factors.33 During conditions of acute inflammation, G-CSF also
facilitates the release of neutrophils from the bone marrow (where 90% of mature
neutrophils reside) into the circulation via the inhibition of the bone-marrow
retention CXCL12 ligand/CXCR4 receptor pathway.34 In addition to suppressing
neutrophil marrow retention, G-CSF actively promotes neutrophil mobilization by
stimulating CXCL1 production in endothelial cells and megakaryocytes. CXCL1 is
the ligand for CXCR2, a highly expressed neutrophil chemotactic receptor.35 The
lung microvasculature also contains a significant pool of mature neutrophils,
which are released into the circulation during inflammation as a result of CXCR4
inhibition.36
Neutrophils utilize four major inflammatory defenses to kill invading
pathogens: phagocytosis, degranulation, neutrophil extracellular trap release
(NETosis) and reactive species generation. In conditions of excessive
inflammation, as seen in overwhelming infection and extensive tissue injury,
these defenses can also exacerbate tissue damage.37
Neutrophil phagocytosis is an important component of the immune
response, characterized by the rapid uptake of microbes opsonized with IgG or
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complement factors into neutrophil phagosomes, which contain destructive
reactive species and hydrolytic enzymes.38 In conditions of excessive
inflammation, phagocytic receptors on neutrophils encounter large complement
or immune complexes that they cannot ingest, a phenomenon known as
frustrated phagocytosis.37 As a result, neutrophils release massive amounts of
granules within the vasculature, resulting in vessel degradation and tissue
hemorrhage.39 This type of uncontrolled neutrophil granule release has been
implicated in secondary tissue injury in both infection and inflammatory
diseases.37
Neutrophil degranulation occurs when immune activation stimulates the
fusion of neutrophil granules containing an array of proteins with neutrophil
phagosomes (for intracellular killing) or the cell membrane (for membrane
presentation or extracellular release). During neutrophil development, they
sequentially acquire four types of granules with distinct cargo; azurophilic
(defensins, elastase, myeloperoxidase), specific (metalloproteinases, lactoferrin),
gelatinase (arginase, lysozyme, gelatinase) and secretory (alkaline phosphatase,
membrane receptors).31 Upon inflammatory stimulation, neutrophils release their
granules in the reverse order. Therefore, although minor neutrophil activation is
capable of inducing the release of secretory granules, the release of azurophilic
granules requires stronger stimulation.40 Early neutrophil inflammatory responses
consist primarily of the release of secretory, gelatinase and specific granules,
which contain proteins that facilitate cell adhesion, migration through tissue and
pathogen killing. Azurophilic granules represent the last line of defense in
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neutrophil degranulation, and the bactericidal proteins and destructive lytic
enzymes they contain can cause significant damage to surrounding tissue.41
Neutrophils can also release neutrophil extracellular traps (NETs) made of
decondensed chromatin studded with neutrophil granules.42 NETs carry a variety
of neutrophil proteins, including neutrophil elastase (NE), matrix
metalloproteinase (MMP-9) and myeloperoxidase (MPO).42-44 Although NET
formation is an anti-bacterial defense, excess NET formation can cause
extensive damage to host tissues, including vascular injury and clot formation.4548

NET release is dependent on very high levels of intracellular oxidative species,

suggesting the two processes are physiologically coupled.49, 50
Although neutrophils possess the capability to cause tissue damage via a
wide array of functions, their production of reactive oxygen species (ROS) and
the resulting oxidative damage to tissues ris a powerful potential mechanism for
exacerbated secondary injury after ischemic stroke. Neutrophils generate large
amounts of ROS during their respiratory burst, including (O2*), hydrogen peroxide
(H2O2) and hydroxyl radicals (HO-).51 Hydrogen peroxide can then react with
chloride and iodide (halide ions) to produce anti-bacterial hypochlorite (HOCL)
using an enzyme called myeloperoxidase (MPO), abundant in neutrophil
granules.52, 53
In comparison to other cells, neutrophils from both mice and humans have
low oxygen consumption and mitochondrial mass at rest.54, 55 Upon exposure to
inflammatory stimuli, neutrophil oxygen uptake and glucose consumption rise,
accompanied by increased intracellular levels of ROS, results in the phagocyte
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respiratory burst.56, 57 The respiratory burst is largely controlled by the NADPH
oxidase complex of proteins, consisting of both cytosolic (p47phox, p67phox,
p40phox) and membrane-bound (gp91phox, p22phox) subunits.58 Upon
neutrophil activation, NADPH oxidase localizes to both specific granules and the
neutrophil plasma membrane, allowing for electrons in NADPH in the cytosol to
access oxygen and resulting in the formation of superoxide anion.58 Superoxide
is degraded to hydrogen peroxide, which is freely cell permeable and can
mediate intracellular and extracellular effects, including inflammasome activation
and type 1 interferon signaling.58, 59
In addition to the NADPH oxidase complex, inducible nitric oxide synthase
(iNOS) also plays a role in neutrophil radical generation via the production of
reactive nitrogen species (RNS) (Figure 1). Although both ROS and RNS are
important components of the anti-bacterial response, the production of excess
reactive species has been implicated in the pathology of many diseases,
including ischemic stroke. Studies have shown that nitric oxide (NO) produced by
iNOS contributes to injury after ischemic stroke.60-64 Using bone marrow
chimeras, Garcia-Bonilla et al. recently determined that iNOS from infiltrating
neutrophils was sufficient to exacerbate brain tissue damage after ischemic
stroke.65 However, as all studies of pro-oxidative enzymes have all been
conducted using young male mice, the contribution of these factors in aged
subjects remains largely unknown.
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Figure 1. Schematic of the neutrophil oxidative burst. A series of prooxidative enzymes (in red) are responsible for the generation of reactive oxygen
and nitrogen species, while anti-oxidative enzymes and mediators rapidly
facilitate their detoxification, preventing excessive damage to healthy tissues. NO
= nitric oxide, iNOS = inducible nitric oxide synthase, NADPH = nicotinamide
adenine dinucleotide phosphate.
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1.5 The Role of Neutrophils in Ischemic Stroke
Neutrophils represent a likely culprit in ischemic stroke pathology due to
their extensive pro-inflammatory functions (Figure 2).8 Recent studies using in
vivo two-photon microscopy have shown that neutrophils are the earliest
peripheral responders after brain, capable of migrating and adhering to the
nearby cerebral vasculature within minutes of the initial injury.66 Following
adherence, neutrophils can transmigrate across the damaged blood-brain-barrier
into the injured parenchyma, where they release a wide array of inflammatory
mediators that orchestrate the recruitment of subsequent waves of immune
infiltration.8 Under normal conditions, neutrophils play an important role in
protection against infection and the resolution of tissue injury. However, if
neutrophils persist in an injured area, they contribute to chronic inflammation -characterized by over-recruitment of monocytes, high levels of pro-inflammatory
mediators and continual tissue damage.67
Neutrophils differentiate and mature in the bone marrow prior to their
release into the bloodstream. Under basal homeostatic conditions, neutrophils
have a very short circulating half-life, returning to organs for programmed
apoptosis and clearance within 24 hours.68 However, once neutrophils in
circulation have been activated by danger associated molecular patterns
(DAMPs) or cytokines, the apoptotic programming is halted as neutrophils traffic
to the inflammatory site.68
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Figure 2. Neutrophil activation and recruitment following ischemic stroke.
(1) Following stroke, neurons and glial cells within the brain initiate inflammatory
cascades that result in disruption of the blood brain barrier and (2) production of
inflammatory cytokines. These pro-inflammatory factors diffuse into systemic
circulation and result (3) in the upregulated production and release of neutrophils
from the bone marrow via decreased CXCR4/increased CXCR2 expression and
(4) pro-survival and pro-inflammatory signaling cascades in circulating
neutrophils that facilitate their activation and migration across the endothelium
into the brain (5), where they can initiate a wide variety of damaging processes
that further exacerbate tissue damage (6).
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Within tissue, neutrophils have several important defensive functions,
including phagocytosis, oxidative burst, formation of extracellular chromatin traps
(NETs) and degranulation (as discussed above).42, 69 Extracellular levels of
myeloperoxidase (MPO) and neutrophil elastase (NE) are elevated in the serum
of stroke patients, consistent with high levels of neutrophil activation and
degranulation.70
Many pre-clinical studies have shown that blocking immune cell adhesion
molecules (E-selectin, P-selectin, ICAM-1, MAC-1) or stimulatory chemokines
and their receptors (MCP1 and CCR2, CX3CL1 and CX3CR1) results in reduced
neutrophil infiltration and infarct volume following stroke.71-85 Unfortunately, when
similar therapeutic strategies have been attempted in clinical trials of ischemic
stroke, no benefit was seen in patients.8 This is likely due, in large part, to the
fact that many of the targeted molecules are expressed on a variety of immune
and non-immune cells, leading to a high degree of non-specificity and
contributing to unwanted side effects including increased infections and
secondary hemorrhagic transformation.
A recent study examined ischemic stroke in young mice deficient in
neutrophil-specific Mcl1, a protein essential for neutrophil survival during
differentiation. This neutrophil knockout model has allowed for the most specific
assessment of the role of neutrophils in ischemic stroke to date.86 The
investigators found no improvement in neurological deficits in Mcl1 knockout
mice, despite reduced neutrophil infiltration into the brain.86 As improved
functional outcome represents the most important goal of ischemic stroke
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therapeutics, these results suggest that neutrophils do not play a role in
exacerbated tissue injury following ischemic stroke. It is critically important to
note that the Mcl1 study (and all other previous anti-neutrophil studies for
ischemic stroke) utilized only young animals (2-3 months of age). However,
ischemic stroke is largely a disease of aged patients, and age significantly
increases both stroke incidence and the likelihood of death or significant disability
after stroke. It is therefore critical that studies investigating potential therapeutic
targets for ischemic stroke be replicated in aged animals, as age represents a
critical biological factor in stroke pathlogy.2

1.6 Ischemic Stroke and Aging
One of the main barriers to effective clinical translation in stroke research
is the prevalent use of healthy, young animals in pre-clinical experiments.87, 88
The majority of ischemic stroke patients are older than 65, and many of them
have significant co-morbidities (atherosclerosis, hypertension, diabetes mellitus)
that enhance ischemic stroke risk and contribute to poor post-stroke outcome.2
To increase the chances that pre-clinical research will translate into effective
clinical therapies, it is critical to incorporate aged animals into both mechanistic
and therapeutic studies. In addition to the higher incidence of exacerbating comorbidities in aged patients, previous work from our lab and others shows that
age itself has profound changes on both the brain and the peripheral response to
cerebral ischemic injury.89-91
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Age impacts several aspects of ischemic stroke pathophysiology. Cerebral
ischemia commonly results in two different injury territories; a dead ischemic core
injury surrounded by penumbra, the brain tissue that is metabolically impaired but
may still be salvageable.92 As we age, the likelihood of tissue rescue in the
penumbra decreases, resulting in permanent loss of the majority of impaired
tissue.93 Most importantly, the ability to recover function after ischemic stroke is
decreased in older patients, indicating that advanced age may impair cerebral
tissue repair and regeneration.94, 95
In light of this, it is clear that the use of young animals to test therapeutics
for ischemic stroke does not represent an ideal model, since therapies will be
used to treat elderly patients with enhanced ischemic tissue damage and
impaired regeneration potential. Ischemic stroke modeling in aged mice, which
has recently been well-validated by our lab, may better replicate the physiological
background of the typical ischemic stroke patient.96

1.7 The Effects of Aging on Neutrophils
Under normal conditions, neutrophils have short circulating half-lives,
usually returning to the bone marrow, spleen, or liver for clearance within 24
hours of their release.97 Recent evidence has shown that these exhausted
neutrophils, typically identified by their low expression of CXCR2 and CXCR4,
are also characterized by upregulation of the adhesion molecules ICAM-1, Mac-1
and CD44.97-100 Perhaps driven by this increased ability to adhere, exhausted
neutrophils are preferentially recruited into tissues following inflammatory
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challenge. A study by Zhang et al. showed that neutrophils can become
exhausted due to exposure to low-level inflammatory exposure in circulation.100
In the same study, Zhang et al. found that exhausted neutrophils were capable
forming higher levels of ROS and neutrophil extracellular traps (NETs).100
As age is marked by increased chronic, low-level inflammation, it is
possible that hyper-inflammatory, exhausted neutrophils are enriched in the
circulation of aging individuals, significantly altering the inflammatory response to
infection and injury in the aged. Several studies have shown higher levels of
neutrophil infiltration into the lungs after pneumonia in older subjects, compared
to younger subjects.101-103 In response to the same inflammatory stimuli, aged
animals have higher levels of neutrophil-activating chemokines and a prolonged
period of neutrophil infiltration into tissues than young animals.104-107
Neutrophils from aged animals have been reported to produce higher
levels of NETs and ROS compared to young neutrophils upon exposure to
bacterial products.100 Some studies have also reported that the augmentation of
ROS production in neutrophils with age, significantly impacting on injury
outcome.108 Recent work has demonstrated that depletion of neutrophils protects
old, but not young, mice from toxic-induced liver injury.109 However, the specific
mechanism behind the enhanced pathogenicity of aged neutrophils in tissue
injury remains uncharacterized.
Another recent study has shown that neutrophil extracellular traps (NETs)
increase in the circulation following acute ischemic stroke in patients.110
Fascinatingly, this study also found that NETs were significantly increased stroke
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patients over the age of 65 compared to levels found in younger stroke
patients.110
Similar aberrations in neutrophil function with aging have been described
across a wide array of diseases, and it has been suggested that age-related
changes in neutrophil function may be a significant driver of poorer outcomes in
elderly patients.111 It is possible that age-related changes in the acute proinflammatory capabilities of neutrophils can exacerbate secondary tissue injury
after a major inflammatory event like ischemic stroke.

1.8 Conclusions
Ischemic stroke affects millions of people every year, resulting in high
mortality and contributing to a staggering loss in quality-of-life. We have outlined
the detailed pathophysiology of ischemic stroke, including the pathways of
primary initial injury and delayed secondary injury. Currently available stroke
therapies, both of which target primary stroke injury and have a very narrow
therapeutic window, were discussed. Additionally, the detailed pathophysiology
of ischemic stroke was reviewed, with particular attention to the role of excitatory
neurotoxicity and post-stroke inflammation in secondary tissue injury. Within the
scope of inflammation, neutrophils were identified as a likely culprit for
inflammation-related damage after ischemic stroke. We presented several
mechanisms of neutrophil-induced tissue damage that may be critical to stroke,
including their ability produce high levels of reactive species (ROS and RNS).
The role of aging as a major driver of ischemic stroke incidence and poor
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outcome was also discussed. Finally, the very limited known data regarding the
effect of host aging on neutrophil function was reviewed.

1.9 Hypothesis and Research Goals
This dissertation investigates the effects of age on the inflammatory
phenotype of neutrophils, and tests whether age alters the contribution of
neutrophils to stroke pathology. Little is currently known about the effects of age
on neutrophil function, and no studies have yet examined the relationship
between age and the neutrophil response to stroke. The second chapter
examines the relationship between age and stroke outcome in both human
ischemic stroke patients and a mouse model of experimental stroke. The third
chapter tests whether age intrinsically alters neutrophil function, or whether the
neutrophil inflammatory response is dependent on the surrounding environment.
In the fourth chapter, we investigate potential mediators of age-related changes
in post-stroke neutrophil activation, mobilization and function in both mice and
humans. In the fifth and final chapter, we utilize a neutrophil specific monoclonal
antibody to deplete neutrophils after stroke onset, to examine the short and longterm effects of anti-neutrophil depletion after ischemic stroke in both young and
aged mice.
To summarize, I hypothesize that age enhances the pro-inflammatory
phenotype of neutrophils after stroke, particularly reactive species generation,
and contributes to the poor outcome seen in aged subjects. I further hypothesize
that selective neutrophil depletion after stroke will (1) improve behavioral
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outcome preferentially in aged animals and (2) permit examination of the in vivo
pathogenic role of neutrophils in aged animals after ischemic stroke, an issue
that has not been established to date.

To test this hypothesis (Figure 3), I endeavored to:
1. Examine the relationship between age, stroke and neutrophils
a. In clinical ischemic stroke, utilizing demographic data and gene
expression analysis
b. In experimental ischemic stroke, by assessing the effects of age on
neutrophil phenotype, neutrophil mobilization, and stroke outcome
2. Determine if post-stroke anti-neutrophil depletion is differentially protective
in aged mice by
a. Examining the effect of anti-neutrophil depletion on infarct size and
long-term brain tissue atrophy in young and aged mice
b. Examining the effect of anti-neutrophil depletion on mortality and
long-term functional outcome in young and aged mice
3. Elucidate the effects of age on neutrophil inflammatory phenotype by
a. Determining the effects of age on the quantity and quality of braininfiltrating neutrophils in young and aged animals after stroke
b. Examining the influence of organism age on neutrophil cytokine
and chemokine production, post-stroke neutrophil infiltration and
the generation and detoxification of reactive species
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Significance and Impact: This work will improve scientific knowledge regarding
age effects on neutrophil function at baseline and after ischemic stroke. It will
advance clinical practice by testing the utility of neutrophil depletion for the
treatment of ischemic stroke in both young and aged animals, and may provide
the basis for new efficacious therapies applicable to human ischemic stroke.
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Figure 3. Graphical abstract illustrating dissertation specific aims.
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Chapter II
Aging increases stroke mortality and morbidity in patients and an
experimental stroke model
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2.1

Abstract

Purpose: Aging is associated with poor outcome after ischemic stroke. Ischemic
stroke results in the activation and recruitment of peripheral leukocytes, including
neutrophils, to the brain. The purpose of our initial studies was to examine the
relationship between aging, ischemic stroke outcome and the neutrophil
response to stroke in (1) human stroke patients and (2) a mouse model of
ischemic stroke.

Experimental Design: Chart review of medical records and biological samples
from ischemic stroke patients admitted to a major stroke center over a ten-year
period was conducted. Demographic data, stroke severity, outcome data and lab
values (absolute neutrophil and immature neutrophil counts) were obtained via
retrospective chart review. For experimental studies, young (3 month) or aged
(22-24 month) mice were subjected to middle cerebral artery occlusion (MCAO)
or sham surgery. Mortality, weight loss, neurological deficit score, infarct size and
hang-wire test were assessed. Flow cytometry was used to quantify neutrophil
infiltration into the brain after experimental stroke in young and aged mice.

Results: The average age of our stroke patient cohort was 69 years. Patients
discharged to rehab/skilled facilities (high morbidity) or patients who died as a
result of their stroke (mortality) were found to be significantly older than those
who were discharged home (low morbidity). Ischemic stroke patients had
significantly higher circulating neutrophil counts than control patients 24 hours
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after symptom onset, and neutrophil count in stroke patients was positively
associated with increasing stroke severity. Stroke severity was also positively
associated with circulating counts of immature “band” neutrophils. In animal
studies, young animals had significantly larger infarcts and higher levels of
edema than aged animals. Aged animals showed significantly higher mortality,
poorer weight recovery, poorer behavioral performance and more severe
neurodeficit scores than young animals.

Conclusions: Age significantly impacts ischemic stroke mortality and morbidity
in human stroke patients and in an experimental mouse model. Circulating
mature and immature neutrophil counts increase acutely in stroke patients in a
severity-dependent manner. As seen in human patients, aged mice experienced
higher mortality and poorer functional outcomes compared to young mice. Taken
together, these results indicated that MCAO in aged mice is a good candidate
model for the study of age-related neutrophil pathogenicity in ischemic stroke.
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2.2 Introduction
Stroke incidence increases dramatically with age, with the majority of
strokes occurring in patients older than 65 years of age.2 The increased
incidence of stroke during advanced age is associated with an age-related
increase in stroke risk factors, including atrial fibrillation, diabetes,
hyperlipidemia, coronary artery disease and hypertension.112, 113 Epidemiological
studies show that aging is also associated with poorer functional outcome after
stroke.3, 114, 115 Unfortunately, while thrombolytic and clot retrieval therapy can
significantly improve stroke prognosis for patients, recent clinical research has
shown that advanced age also increases the chances of poor outcome after IV
tPA or intra-arterial therapy.116, 117 The uniquely high burden of stroke in the
elderly, coupled with evidence that current therapeutics are less effective in aged
patients, underscores the need for novel treatment modalities that can improve
outcome in aged stroke patients.
Recent work in the field of ischemic stroke has shown that aging has a
significant impact on stroke outcome in mouse models, closely mirroring the
patterns seen in ischemic stroke in humans.96 The impact of aging on brain
physiology and injury is multifactorial, involving systemic changes throughout the
body in addition to alterations in the central nervous system itself.118
Inflammation has been increasingly recognized as a driver of age-related tissue
dysfunction, a phenomenon known as “Inflammaging.”119 Inflammation is typically
caused by tissue injury or pathogenic infection, and usually resolves once the
pro-inflammatory stimulus has been eliminated.120 During conditions of long-term
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or excessive inflammatory response, this resolution can fail, leading to a
consistent state of non-productive, non-resolving inflammation. Inflammaging is
characterized by a gradual increase in pro-inflammatory immune activation as an
organism ages, which is believed to be largely driven by cells of the innate
immune system, including neutrophils.121
Neutrophils and neutrophil-associated inflammatory molecules have
recently been found to predict both initial stroke risk and poor outcome after
ischemic stroke. A study by Buck et al. found that early neutrophilia (within 24
hours of stroke onset) in ischemic stroke patients was significantly predictive of
larger infarct size.122 A higher neutrophil-to-lymphocyte ratio (NLR), a predictor of
poor outcome in a variety of diseases, predicts poor short-term outcome, poor
long-term outcome and the likelihood of hemorrhagic complications in ischemic
stroke patients.123-125 Interestingly, studies have also shown that an elevated
NLR in otherwise healthy patients is a significant independent risk factor for
future ischemic stroke.126 In line with this data, neutrophils play a significant role
in pathological processes that contribute to ischemic stroke risk, including
atherosclerosis and thrombosis (clot formation).127-129 Circulating neutrophil
counts increase within several hours of ischemic stroke onset.130 This increase
likely results from increased neutrophil differentiation, augmented release of
neutrophils from the bone marrow and spleen reservoirs, and suppression of
neutrophil apoptosis.131 However, a significant gap in knowledge remains
regarding the effects of age and inflammaging on neutrophil biology. Most
importantly, we do not yet understand how age-related changes in the
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destructive potential of neutrophils impact patients in conditions of excessive
sterile inflammation, as seen in ischemic stroke.
In order to best model the contribution of neutrophils to ischemic stroke
pathology in patients, it is critical to realize that age may play a major role in
ischemic stroke pathology for many patients. Despite success in animal models,
clinical trials for ischemic stroke therapies have been largely unsuccessful. One
critical barrier to effective therapeutic testing is the lack of pre-clinical testing in
aged animals. To date, the vast majority of experimental stroke research is
performed in young animals. However, ischemic stroke is largely a disease of the
aging, which represents the single strongest independent risk factor for ischemic
stroke.
In this chapter, we aimed to (1) examine the relationship between
ischemic stroke and neutrophil mobilization, (2) confirm the relationship between
aging and increased ischemic stroke mortality and morbidity in human patients
and (3) replicate the age-related increase in poor stroke outcome in a mouse
model of ischemic stroke.

29

2.3 Materials and Methods
Retrospective Chart Review: Chart review was conducted on patients admitted to
Hartford Hospital (Hartford, CT) between 2005-2015. Hartford Hospital is a 868bed community-based teaching hospital certified as a JCO Comprehensive
Stroke Center (CSC). Inclusion criteria were defined as ischemic stroke and
transient ischemic attack (TIA) patients with known age, initial stroke severity and
discharge disposition (n = 3635). TIA was defined as a brief and resolving acute
onset focal neurological deficit. TIA patients were chosen as a control group as
they have similar characteristics to stroke patients, including co-morbidities and
age distribution. Ischemic stroke was defined as acute-onset focal neurological
deficits with corresponding evidence of cerebral infarction on radiographic
imaging (CT or MRI). Exclusion criteria were defined as ischemic stroke
secondary to dissection, iatrogenic stroke or equivocal imaging. Human subject
data for the demographic cohort are included in Table S1. The primary functional
outcome was designated as initial stroke severity, as measured by National
Institutes of Health Stroke Score Scale (NIHSS) on admission. Statistical
analysis: Linear regression analysis was used to examine the association
between patient age and NIHSS admission severity (as a continuous variable).
The secondary functional outcome was designated as discharge disposition, as a
method of determining mortality (death or discharge to hospice) and morbidity
(significant disability requiring significant rehabilitation or long-term care).
Discharge disposition was categorized into three groups: Home with or without
services (low morbidity), discharge to sub-acute or acute rehab (high morbidity),
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or death/hospice discharge (death). The relationship between discharge
disposition and age was examined via Kruskal-Wallis testing.

Absolute Mature and Immature Neutrophil Counts: Patients from the
demographic data cohort (n=3635) with available lab results were screened for
this analysis. Exclusion criteria included active cancer, autoimmune disease,
iatrogenic stroke and active immunosuppressive therapy. TIA control (n = 91)
and ischemic stroke patients (n = 364) with available absolute mature neutrophil
and immature band neutrophil counts within 24 hours of hospital admission were
included in the analysis. Human subject data for the lab value cohort are
summarized and included in Table S1. Statistical analysis: Differential neutrophil
counts were analyzed by two-tailed Mann-Whitney test. The associations of
neutrophil counts with age and stroke severity were analyzed by linear
regression, followed by multivariate multiple regression to control for potential
confounding variables.
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Cohorts

Stroke Outcome
(Severity, Mortality and
Morbidity)
69.3 ± 15.6 yr

Absolute Neutrophil
Count

Sex (Female, %)

50.5 %

50.3 %

N

3635

638

Age

75.7 ± 9.9 yr

(Mean ± SD)

Table S1. Patient Characteristics for Stroke Outcome and Neutrophil Count
Studies. The average age, sex composition and n is given for the demographic
outcome and absolute neutrophil count cohorts studied in Chapter 2. * SD =
Standard Deviation; yr = year
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Animal Information
Young adult (3-4 mo) and aged (20-22 mo) C57BL/6J male mice were grouphoused in a specific pathogen facility on a 12h light/dark cycle. Aged animals
were purchased at 12 months of age and continued to age in house for 8-10
months. Animals had access to water and chow ad libitum. All animal
procedures were performed in accordance with NIH guidelines for the care and
use of laboratory animals and approved by the University of Texas Health
Science Center at Houston.

Middle Cerebral Artery Occlusion (MCAO) Model of Ischemic Stroke
Young (3-4 mo) and aged (22-24 mo) C567BL/6 mice were obtained from
Jackson Laboratories or the National Institute of Aging. Animals were randomly
assigned to MCAO or control groups. One surgeon performed all surgeries,
which were randomized and distributed over days to reduce variation. Mice were
subjected to focal transient cerebral ischemia by 60 min of reversible MCA
occlusion under Isofluorane anesthesia as previously described.132 In order to
achieve equivalent levels of occlusion, 0.21 mm and 0.23 mm silicone coated
sutures (Coating Length 2.5mm, Doccol) were used to occlude the MCA in young
and aged mice, respectively.132 Rectal temperatures were maintained at
approximately 37° C during surgical ischemia with an automated temperature
control feedback system. For verification of adequate ischemia, cerebral blood
flow (CBF) was measured via Laser Doppler flow measurement (Moor
Instruments), as previously described.133
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Infarct Quantification
Aged and young animals were sacrificed 24 hours post-stroke. Following
sacrifice, brains were removed and flash frozen at -80°C. Brains were then sliced
into 2mm coronal sections, and stained with 1.5% 2,3,5-triphentyltetrazolium
(TTC, Sigma-Aldrich). Sections were fixed in 4% paraformaldehyde overnight
before digital imaging and infarct measurement (Sigma Scan Pro5) by a blinded
investigator as previously described.134

Neurological Scores
Neurological scores were recorded in mice at the time of reperfusion, and then
once daily for seven days post-MCAO surgery. Neurological scoring was
performed by an observer blinded to treatment group. In long-term outcome
studies, neurological scoring was repeated at 7, 14, 21, 28 and 54 days. The
scoring system is as follows: 0, no deficit; 1, forelimb weakness and turning of
the torso to the ipsilateral side when held by tail; 2, circling towards the affected
side; 3, unable to bear weight on affected side; and 4, no spontaneous locomotor
activity or barrel rolling, as previously described.135

Hanging Wire Test. In this test, mice utilize all four limbs to support their body
weight on a wire-cage elevated 36 inches above a cage containing soft bedding.
The time until the mouse fell was recorded, with an upper limit of 90 seconds.
Mice unable to hang were excluded from the study. For trials involving aged
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mice, the average hang time was corrected for weight, to adjust for the weight
variability within the cohort.

Sacrifice and Tissue Collection
Mice were first anesthetized using 2,2,2- Tribromoethanol (Sigma-Aldrich, St.
Louis, MO). Arterial blood was harvested via intracardiac puncutre into a 1ml
syringe pre-coated with 1,000U heparin sulfate. For flow cytometric studies,
animals were transcardially perfused with 60ml of sterile, cold PBS. The organs
of interest (brain, lungs, femoral bone marrow and spleens) were subsequently
collected and rinsed with cold, sterile PBS before processing.

Flow Cytometry. Sham and stroke animals were anesthetized 24 hours after
MCAO surgery and blood was obtained via intracardiac puncture, followed by 3
rounds of RBC lysis with Tris-ammonium chloride (Stem Cell Technologies).
Mice were transcardially perfused with 60 mL of sterile, cold PBS. Brains were
collected and the olfactory bulbs, brainstem and cerebellum were removed. The
cerebrum was divided into two hemispheres, and the ipsilateral (stroke)
hemisphere was prepared for flow cytometry. Hemispheres were mechanically
processed with a razor blade before enzymatic digestion in collagenase/dispase
(Roche Diagnostics) and DNAse (Roche Diagnostics) at 37°C for 1 hour.
Following incubation, the cells were filtered through a 70um filter screen, followed
by leukocyte enrichment via density centrifugation (70%/30% Percoll, GE
Lifesciences). Cells were washed twice with ice-cold PBS, followed by a 30
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minute RT incubation with an amine-reactive viability stain (Ghost Dye 510,
Tonbo Biosciences). Cells were spun down and re-suspended in FACS Buffer
(PBS + 2% FBS) containing Fc Receptor Blocker CD16/32, 1:100 for 10 minutes
at room temperature.

Neutrophil Identification Flow Cytometry Panel: Following this blocking step, cells
were re-suspended in the following cocktail of fluorescently conjugated
antibodies: CD45-vf450 (Tonbo Biosciences), CD11b APC-Cy7 (Tonbo
Biosciences), Ly6G-PeCy (Tonbo Biosciences) and Ly6C-PeCF594 (BD
Biosciences) and incubated for 30 minutes at room temperature. After staining,
cells were washed twice and re-suspended in 300ul FACS buffer for analysis on
a Cytoflex S Flow Cytometer (Beckmann Coulter). Data files were analyzed using
FlowJo (TreeStar). The representative gating strategy used is given in Figure
S1. Positive and negative populations were defined using fluorescence minus
one (FMO) controls.
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Figure S1. Gating strategy for neutrophil identification (brain). Following
gating for singlets and viability, immune cells are identified by their expression of
the pan-immune cell marker CD45 and their expression of the myeloid lineage
marker CD11b. Microglia, the resident immune cells of the brain, are identified as
CD11b+/CD45Intermediate cells. Peripheral immune cells are identified as CD45High
cells, with peripheral myeloid cells identified as CD11b+/ CD45High. Out of these
peripheral myeloid cells, neutrophils are then defined as Ly6CIntermediate/Ly6GHigh.
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2.4 Results
Age influences stroke incidence, mortality and morbidity in human patients.
Age has been implicated as a significant risk factor for both stroke incidence and
poor stroke outcomes. To examine the relationship between age and stroke in
our patient population, we conducted a retrospective chart review of patients
admitted to a primary stroke care center over a 10-year period (Figure 4). We
found that the average age of stroke patients in our demographic cohort was 69
years (Figure 4A). Increasing age was significantly associated with greater initial
stroke severity (Figure 4B, p<0.0001), as measured by the NIH Stroke Scale.
Using discharge disposition as a measure of functional outcome, we found that
patients with low morbidity at discharge were significantly younger (63.57 ± 15.01
years) compared to patients in the high morbidity (72.15 ± 14.75 years) and
mortality (79.2 ± 12.56 years) groups (p<0.0001, Figure 4C).

Circulating neutrophil counts are increased in stroke patients in a severitydependent manner. To determine the relationship between ischemic stroke and
neutrophil mobilization, we examined retrospective records of absolute mature
and immature “band” neutrophil counts in ischemic stroke patients and TIA
controls (Figure 5). Absolute mature neutrophil counts demonstrated that
ischemic stroke patients have higher neutrophil counts (6049 ± 2952
neutrophils/ul) compared to controls (4955 ± 1984 neutrophils/ul) 24 hours after
symptom onset (p=0.0005, Figure 5A). Linear regression analysis within stroke
patients demonstrated that neutrophil counts were significantly correlated with
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increasing stroke severity (p<0.0001, Figure 5B). However, neutrophil counts in
stroke patients were not significantly associated with patient age (p=0.80, Figure
5C). As emergency granulopoiesis can be accompanied by an increased release
of immature bone marrow neutrophils, or “bands”, from the bone marrow, we also
assessed the effects of stroke on circulating band counts. There was a trend
towards higher immature neutrophil counts in stroke patients (28.35 ± 29.09
cells/ul) compared to controls (22.31 ± 16.54 cells/ul), although this difference did
not reach statistical significance (p=0.13, Figure 5D). Within stroke patients, a
significant correlation between stroke severity and increased circulating band
count was observed (p=0.0018, Figure 5E). As with mature neutrophils, no
significant effect of age on band counts within stroke patients was seen (p=0.49,
Figure 5F). Multivariate multiple regression analysis was then performed, which
confirmed that both mature (p=<0.0001) and immature (p=0.0006) circulating
neutrophil counts increase with increasing stroke severity. No significant
independent contribution of patient age or sex was seen.
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Figure 4. Age, stroke incidence and stroke outcome of patients admitted to
a major stroke center (n=3635). A. Distribution of age at stroke onset. B.
Correlation of age vs. baseline stroke severity. C. Relationship between patient
age and stroke outcome at discharge.
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Figure 5. Association between injury severity (NIHSS deficit score) and
circulating neutrophil counts within stroke patients. Blood from stroke
patients or controls 24 hours after onset. A. Mature neutrophil counts in stroke
(n=508) and TIA control patients (n=130). B. Mature neutrophil count and stroke
severity, as measured by NIHSS on admission. C. Mature neutrophil counts and
stroke patient age. D. Immature band counts in stroke and control patients. E.
Immature band neutrophil count and stroke severity. F. Immature band neutrophil
counts and stroke patient age.
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Age exacerbates poor stroke outcome in a mouse model
To examine the effect of age on stroke outcome in an animal model, we
performed a 60 minute MCAO in young (3-4 mo) and aged (22-24 mo), with
close monitoring of cerebral blood flow. In line with previous work in our lab, this
model is capable of achieving similar degrees of cerebral ischemia in young and
aged mice (Table 1).96 Aged mice weighed significantly more than young mice
(p=0.0002), due in large part to excess fat deposition. Importantly, internal
temperature during surgery was also equivalent between young and aged mice.
Ischemic stroke histology data from young and aged animals is presented in
Figure 6. Despite similar levels of cerebral blood flow reduction, young animals
had significantly larger stroke sizes (Figure 6A, 6B) and a greater degree of
edema (Figure 6C) than aged animals.
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Age

Weight (g)

CBF Reduction (%)

Temperature (C)

Young

26.24 ± 1.11

89.54 ± 2.70

36.60 ± 0.46

34.68 ± 1.93

89.86 ± 1.76

36.82 ± 0.55

p=0.0002

n.s.

n.s.

(3 months)
Aged
(20-22 months)
Significance

Table 1. Ischemic stroke model parameters in young and aged mice. Young
and aged mice were subjected to right MCAO stroke surgery. Weight (mean ±
SD), cerebral blood flow (CBF) reduction (% of baseline, mean ± SD) and
temperature during stroke (mean ± SD) are given.
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Figure 6. Aged animals experience smaller infarcts and decreased edema
following ischemic stroke. Young (3 month) and aged (24 month) mice were
subjected to 60 minute MCAO. Brains were stained with TTC and infarct and
edema were calculated (n=3/group) A. Representative TTC of 24 hour infarcts in
young and aged mice. B. Infarct measurements of cortex, striatum and whole
hemisphere. C. Edema quantification. *=p<0.05, **p<0.01

44

However, despite reduced infarct size, aged animals have significantly
poorer outcomes following ischemic stroke compared to young animals (Figure
7). Post-stroke mortality at 7 days was significantly higher in aged animals than
in young animals (50% vs. 8.3%, p=0.03, Figure 7A). Although weight loss was
initially higher in young animals (due to lower starting body weights), aged
animals failed to begin weight recovery 4-5 days after stroke, resulting in
significantly greater weight loss by day 7 post-stroke (p=0.005, Figure 7B).
Neurodeficit scoring, an important measure of gross neurological dysfunction,
was also significantly worse over the initial stroke recovery period (Figure 7C). In
addition, hang-wire testing demonstrated significantly poorer strength recovery in
aged animals 7 days post-stroke than in young animals (p=0.009, Figure 7D).
These results are congruent with detailed behavioral testing done previously in
our lab, demonstrating an overall poorer outcome for aged animals following
ischemic stroke.96
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Figure 7. Aged animals have poorer outcomes after ischemic stroke. Young
(3 month) and aged (22-23 month) mice were subjected to 60 minute MCAO and
followed for seven days. A. Mortality after stroke. B. Weight loss (as a
percentage of baseline weight) over 7 days after stroke. C. Neurodeficit scores
(NDS) over time. D. Hangwire test, corrected for weight and age-matched control
performance. *=p<0.05, **p<0.01, ***=p<0.001, ****p<0.0001. n=12-14/grp for
stroke mortality, weight loss and NDS, n=4-6 for hangwire testing.
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Age does not alter neutrophil infiltration into the brain 24 hours after stroke. In
order to confirm that neutrophils infiltrate the brain within 24 hours of experiment
stroke, we performed flow cytometry on the ipsliteral brain hemisphere from
young and aged stroke mice. Neutrophils were identified as
CD45High/CD11b+/Ly6G+ cells, as demonstrated by the gating strategy shown in
Figure S1. Stroke significantly increased neutrophils in the brain, both
proportionally (p=0.0005) and by absolute counts (p=0.0007). However, no
significant age difference in neutrophil infiltration into the stroke brain was
observed.
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Figure 8. Age does not alter neutrophil infiltration into the brain at 24
hours. Flow cytometry was performed on the ipsliteral hemisphere of young and
aged mice subjected to 60 minute MCAO sham or stroke surgery. Brain
neutrophils (as a % of live, and absolute counts) are compared. ***=p<0.001,
n=3-4/grp

48

2.5 Discussion
This study confirmed that the vast majority of patients in our cohort were
over the age of 65, with a median age of 69 years. In addition, we corroborated
previous reports of a positive association between patient age and increasing
stroke severity. In addition, we also found that older stroke patients were more
likely to die or require advanced rehabilitation compared to younger patients.
Subsequently, our examination of a subset of patients with available
absolute neutrophil counts within 24 hours of admission found that stroke
patients have higher levels of circulating neutrophils compared to in-hospital,
risk-factor matched controls. Additionally, we demonstrated that circulating
neutrophil counts increase proportionally to initial stroke severity. Our data is in
agreement with published work demonstrating that high levels of neutrophils in
the circulation correlate with an increased in stroke severity and poorer functional
outcomes.122, 136, 137
Although our work was limited to circulating neutrophils, previous research
in patients has shown that the timing of neutrophil accumulation into the brain
occurs in concert with increases with circulating neutrophils (beginning within 6
hours and peaking at 24 hours post-stroke), and that higher neutrophil
accumulation in the brain is significantly correlated with poorer neurological
outcome and larger infarct volumes.138 We found that post-stroke neutrophilia is
positively associated with increased stroke severity, indicating that anti-neutrophil
therapy may be best applied to patients with significant stroke volumes.
Interestingly, we found no significant association between peripheral neutrophil
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count after stroke and patient age. This suggests that age does not alter
neutrophil number after stroke in the circulation, indicating that differences in
neutrophil-mediated damage in aged stroke patients may instead be driven by
differences in neutrophil phenotype.
Our data confirms that age is linked to both increased stroke incidence
and poorer functional outcome after stroke in human patients. These results
highlight the importance of using aged models pre-clinical studies for stroke
therapies, as the vast majority of the population requiring treatment will be aged.
Next, we performed experimental animal studies in young and aged mice
to confirm that age-related increases in ischemic stroke mortality and morbidity
can be replicated in an animal model. In line with previous work done by our lab,
young male mice had larger infarcts and greater levels of cerebral edema than
aged male mice, despite similar reductions in cerebral blood flow. Using flow
cytometry, we found that stroke results in significant neutrophil infiltration into the
brains of both young and aged animals 24 hours after injury onset. No difference
was seen in absolute neutrophil infiltration between young and aged animals.
This suggests that, as in human patients, age does not significantly increase the
magnitude of neutrophil mobilization recruitment at 24 hours.
Despite a larger initial injury size in young mice, aged male mice were
found to have significantly poorer outcomes after ischemic stroke, including
increased neurodeficit scores, higher mortality, poorer behavioral outcomes and
an inability to regain weight. These drastic age differences in outcome illustrate
the importance of examining (1) the driving mechanisms behind poor recovery in
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aged mice after brain injury and (2) the testing of future therapeutics in animals
across the lifespan.
In Chapter 2, we have shown that age significant increases the mortality
and morbidity of ischemic stroke in both human patients and in an experimental
mouse model (Figure 9). However, whether age impacts the inflammatory
function of neutrophils remains unknown. In Chapter 3, we will examine the
effects of age on the inflammatory functions of neutrophils in vivo and ex vivo.
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Figure 9. Graphical abstract illustrating findings from Chapter 2
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Chapter III
Age augments neutrophil reactive species generation in a
location-specific manner
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3.1

Abstract

Purpose: Initial studies performed in ischemic stroke patients and a mouse
model of ischemic stroke demonstrated that age exacerbates neurological
deficits, mortality and functional loss. In this series of experiments, we examined
the effects of age on neutrophil cytokine secretion and neutrophil reactive
species production, two major potential causes of neutrophil-mediated tissue
damage.

Experimental Design: Serum levels of inflammatory cytokines in neutrophils
from young and aged mice was measured via multiplex ELISA. The production of
reactive species in the blood and bone marrow neutrophils of young and aged
mice was analyzed by flow cytometry. Protein levels of reactive-species
generating and neutralizing enzymes in isolated young and aged neutrophils
were measured by Western Blot. Finally, we examined the reactive species
content of bone marrow resident neutrophils and brain-infiltrating neutrophils in
young and aged animals after ischemic stroke.

Results: Our results indicated that age does not significantly affect cytokine and
chemokine production from naïve, bone marrow neutrophils. Similarly, age did
not effect the generation of reactive species or protein levels of pro-oxidative
(NOX2, iNOS)/anti-oxidative enzymes (Catalase, SOD1). However, circulating
neutrophils from aged mice were found to be larger, more granular and more
likely to produce reactive species than young neutrophils after ex vivo
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stimulation. In addition, brain-infiltrating neutrophils in aged animals had
significantly higher neutrophil reactive species content than those in young
animals after ischemic stroke.

Conclusions: We determined that, while cytokine production and reactive
species production is similar in young and aged bone-marrow neutrophils,
circulating and brain-infiltrating neutrophils from aged animals produce higher
levels of reactive species than young neutrophils. These results suggest that
age-related alterations in neutrophil function are not cell-intrinsic, but may instead
result from signals present in the systemic circulation and injured tissue of aged
animals.
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3.2 Introduction
Although neutrophils have traditionally been considered as effector
“soldiers” of the immune system, recent work has shown that neutrophils are also
capable of producing a wide variety of inflammatory cytokines and chemokines.
These neutrophil-derived factors, which are capable of reacting with a wide
variety of innate and adaptive immune cells, can play a significant role in the
regulation of the immune system.139 In this Chapter, we will measure the ability of
neutrophils from young and aged animals to produce cytokines and chemokines
at baseline and after inflammatory stimulus.
In addition to inflammatory cytokines, neutrophils are also capable of
producing large amounts of reactive species upon stimulation. An increase in
reactive species generation has been implicated in many age-related diseases
and inflammatory conditions.140 In the majority of cells, free radicals are
necessary byproducts of cellular metabolism and respiration, and also play a key
role in intracellular signaling. Phagocytic immune cells, including neutrophils, can
also harness the production of free radicals into an anti-microbial “oxidative
burst.”141 The primary source of reactive oxygen species in neutrophils is NADPH
oxidase (NOX2), which is capable of generating superoxide anions without
mitochondrial involvement.142 Reactive nitrogen species are also produced in
large quantities within neutrophils by the enzyme inducible nitric oxide synthase
(iNOS). Previous studies have reported that neutrophil-specific iNOS is a major
driver of poor outcome after ischemic stroke in mice.65 Superoxide dismutase is
the primary enzyme responsible for catalyzing the reaction of superoxide anions
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(O2-) into hydrogen peroxide (H2O2), which is then further detoxified by catalase
into H2O and O2. While the oxidative burst is beneficial under conditions of
infection, if left unchecked, excessive build-up of reactive species within
neutrophils has been implicated in the exacerbation of tissue damage.143
In this chapter, we tested potential characteristics of aged neutrophils
believed to contribute to their heightened pathogenicity in aged mice after
ischemic stroke. To that end, we examined whether age significantly altered (1)
neutrophil cytokine production and (2) neutrophil reactive species production.
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3.3 Materials and Methods
Neutrophil Isolation.
For experiments requiring isolated neutrophils, mice were anesthetized and
transcardially perfused with 60ml ice-cold PBS prior to cervical dislocation. All
long bones of the forelimbs and hindlimbs were dissected out, cleaned of muscle
and fat and washed in 70% ethanol. Bones were then crushed in a small mortar
and pestle containing 5ml of Hanks Balanced Salt Solution (HBSS) without
calcium and magnesium, supplemented with 2% heat-inactivated fetal bovine
serum, in order to remove the bone marrow. The resulting bone marrow
homogenate was filtered through a 40um cell strainer into a 50ml falcon tube,
then washed twice with HBSS + 2% FBS. The bone marrow cells were then resuspended in 1ml room temperature HBSS and layered onto a gradient made of
Histopaque-1.077 (3ml) and Histopaque-1.119 (Sigma). Cells were centrifuged at
500g for 30 minutes at room temperature with the brake off, mononuclear cells at
the HBSS/1.077 interface were removed and discarded, and neutrophils were
collected at the 1.077/1.119 interface. Cells were then washed twice with HBSS
+ 2% FBS and re-suspended in 500ul HBSS before negative magnetic isolation
via the Stem Cell Mouse Neutrophil Isolation Kit (Stem Cell Technologies).

Cytokine Analysis. Isolated neutrophils were incubated with 0, 50 or 200 nM PMA
at 37°C for 45 minutes. After stimulation, the supernatant was collected and
frozen down at -80°C until use. Samples were thawed and chemokine levels
were measured in plasma using the Bio-Plex Pro Mouse Chemokine Assay (Bio-
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Rad), on a Bio Plex 200 Luminex System. Cytokine and chemokines with
detectable supernatant levels were then analyzed by multiple T-testing, with
correction for multiple comparisons, in order to determine the effects of PMA
stimulation on neutrophil chemokine production.

Single-Cell Arterial Blood and Brain Suspension Preparation
Arterial blood was subjected to three rounds of 10 minute RBC lysis on ice using
Tris-ammonium Chloride (Stem Cell Technologies, Cambridge, MA) at 9:1, 4:1
and 4:1 stringencies. The remaining white blood cells were washed twice with
500ul of cold PBS, then placed in 1ml of supplemented RPMI (Life Technologies)
containing L-glutamate, 2.5% HEPES Buffer, 1X Pen-Strep, 5% heat-inactivated
FBS until staining. Spleens and bone marrow were removed, mechanically
disrupted and filtered through a 70um filter screen, followed by 1 round of RBC
lysis with Tris-ammonium chloride. Brains were split into ischemic and nonischemic hemispheres, then placed into a petri dish containing 5ml of
supplemented RPMI and mechanically diced with a razor blade. Brains were then
chemically digested with collagenase/dispase (1mg/ml, Roche Diagnostics) and
DNAse (10 mg/ml, Roche Diagnostics for 45 minutes at 37°C. After filtration
through a 70um filter, the brain homogenate was applied to a 30%/70% Percoll
gradient. After centrifugation, brain leukocytes were harvested from the gradient
interface and washed with 10ml of supplemented RPMI, then re-suspended in
1ml of flow cytometry buffer (FACS Buffer: 1X Sterile PBS, 2% Heat-Inactivated
Calf Serum) for further staining.
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In Vivo ROS Assay. Single-cell brain and bone marrow suspensions were
washed twice in 1X sterile, cold PBS, followed by viability staining with Ghost
Dye 510 (Tonbo Biosciences) for 30 minutes in the dark at room temperature.
Cells were centrifuged at 500g for 5 minutes at 4°C, the supernatant was
discarded and the pelleted cells were re-suspended in 100ul of 1:100 FC
Receptor Block (Tonbo Biosciences) for 10 minutes at room temperature. Cells
were then stained with following surface antibodies: CD45-vf450, CD11b-APCCy7, Ly6G-Pe-Cy7, Ly6C-APC (Tonbo Biosciences) for 30 minutes at room
temperature, protected from light. Following surface staining, samples were
incubated with dihydrorhodamine 1,2,3 (DHR) and 200 nM PMA for 45 minutes
at 37°C according to the manufacturer’s instructions (Neutrophil Monocyte
Respiratory Burst Assay Kit, Cayman Chemical), then washed and analyzed
immediately for rhodamine fluorescence on a Beckmann Coulter Cytoflex S Flow
Cytometer. Data was analyzed using FlowJo (TreeStar).

Ex Vivo ROS Assay.
Neutrophils isolated as described above were then counted and diluted to a
concentration of 1x10^6 cells/ml. Cells were stained with surface markers
mentioned above (CD45, CD11b, Ly6G, Ly6C). Following surface staining,
dihydrorhodamine 1,2,3 dye (DHR), PMA and incubation buffer were used
according to manufacturer’s instructions (Neutrophil Monocyte Respiratory Burst
Assay Kit, Cayman Chemical). 100ul of cells were taken and incubated with DHR
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and various concentrations of PMA (0, 25, 50, 100, 200, 400 nM PMA) for 45
minutes at 37°C. Flow cytometry was used to identify neutrophils, and measure
median fluorescence intensity of the DHR signaling per cell.

Western Blotting.
Neutrophils were isolated as described above, counted and diluted to a
concentration of 1 x 10^6 cells/ml. Cells were washed twice with ice cold PBS
and immediately placed on ice. Cell pellets were then lysed by the addition of
100ul of lysis buffer: 1X TBS, 0.1% NP-40, Protease Cocktail (Sigma),
COMPLETE Protease Inhibitors (Roche) and PHOS-Stop (Roche). Cells were
incubated on ice for 15 minutes, followed by centrifugation at 12,000g for 20
minutes at 4°C. The supernatant was removed and 4X loading buffer (Bio-Rad)
containing 2-mercaptoethanol was added before boiling at 100°C for 5 minutes.
Samples were stored at -80°C until use. For western blotting, samples were run
on Criterion Gels (Bio-Rad, 12%) for 1 hour at 90V, followed by transfer to PVDF
membrane (3 hours at 60V). Membranes were blocked with 5% BSA in TBST,
followed by incubation with one of the following primary antibodies overnight at
4°C: iNOS (Rabbit anti-mouse, Abcam) at 1ug/ml, SOD1 (Rabbit anti-mouse,
Abcam) at 1:2000, NOX2 (Rabbit anti-mouse, Abcam) at 1:500 and Catalase
(Rabbit anti-mouse, Abcam) at 1:500 in TBST. After washing three times in
TBST, membranes were incubated with HRP Conjugated Goat Anti-Rabbit
secondary antibody (Vector, 1:20,000 in TBST) for 1 hour at room temperature.
After washing three times in TBST, cells were incubated for 5 minutes with ECL
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Western Blotting Substrate (Thermo Fisher) before visualization on a Bio-Rad
ChemiDoc XRS system. HRP-conjugated anti-mouse B-actin (Sigma) was used
as a loading control. Data were analyzed by two-way ANOVA, followed by
Sidak’s multiple comparisons test.
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3.4 Results
In the following experiments, we sought to examine the effects of age on the
ability of neutrophils to produce (1) inflammatory cytokines and chemokines and
(2) reactive oxygen species.

Age Does Not Affect the Production of Neutrophil-Derived Cytokines and
Chemokines. Neutrophils were cultured for one hour with no stimulation, 50 nM
of PMA or 200 nM PMA. The supernatant was then collected and
cytokine/chemokine production was measured by multiplex ELISA. Out of 32
valid analytes, neutrophils were found to secrete detectable amounts of 22
cytokines and chemokines. Of these, 11 were found to be significantly
upregulated by exposure to the inflammatory activator PMA, after adjustment for
multiple testing (Table 2). PMA treatment significantly increased neutrophil
secretion of the inflammatory cytokines IL-6 and TNFa, as well as a significant
upregulation in the secretion of several lymphocyte chemokines (CCL25,
CXCL13, CXCL10, CCL17). Importantly, neutrophils also showed a dramatic
upregulation of monocyte and neutrophil-associated chemokines, including
CCL4, CCL3, CXCL2 and CXCL12.
Samples were then separate based on the age of the donor mouse, in
order to allow the examination of age effects on neutrophil chemokine secretion.
(Figure 10). No significant differences were seen in inflammatory cytokine or
chemokine production in young and aged neutrophils across all stimulation
conditions.
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Table 2. Neutrophil production of inflammatory chemokines and cytokines
Analyte (pg/ml)

0 nM PMA

50 nM PMA

q value

FC

CXCL2

214.3 ± 2.31

248.60 ± 64.76

<0.0001

32.92

CCL3

104.3 ± 1.27

122.30 ± 43.18

<0.0001

26.75

CXCL12

373.5 ± 20.07

323.40 ± 112.11

0.0001

10.66

CCL4

38.41 ± 3.54

69.87 ± 23.80

0.0001

3.44

IL-6

2.97 ± 0.42

5.59 ± 1.16

<0.0001

1.59

TNF-a

14.65 ± 2.60

18.90 ± 2.72

<0.0001

1.39

CCL17

2.89 ± 0.76

4.93 ± 0.83

0.0002

0.97

CXCL13

199.80 ± 31.42

256.30 ± 32.92

0.002

0.62

CCL24

131.60 ± 19.62

101.90 ± 33.79

n.s.

0.57

CCL5

15.14 ± 3.60

12.78 ± 5.96

n.s.

0.55

CXCL10

83.23 ± 11.10

101.30 ± 9.58

0.0001

0.51

CCL25

174.40 ± 36.75

231.00 ± 43.93

0.03

0.36

CCL20

6.73 ± 1.26

6.85 ± 1.19

n.s.

0.28

CX3CL1

19.86 ± 4.51

26.15 ± 2.10

0.04

0.26

CCL1

2.03 ± 0.50

2.67 ± 0.79

n.s.

0.25

CCL27

306.40 ± 77.50

413.30 ± 45.75

n.s.

0.18

CCL7

1.32 ± 0.49

1.83 ± 0.28

n.s.

0.05

IFN-y

4.90 ± 2.20

6.02 ± 0.99

n.s.

0.01

IL-10

38.60 ± 17.62

63.20 ± 14.52

n.s.

-0.01

CXCL11

33.46 ± 17.88

41.88 ± 9.40

n.s.

-0.08

IL-16

86.37 ± 25.70

77.87 ± 45.03

n.s.

-0.21

IL-1B

30.04 ± 17.16

28.39 ± 9.24

n.s.

-0.3
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Figure 10. Heat map of differentially expressed cytokines and chemokines
in young and aged cultured neutrophils. Neutrophils were isolated from
murine bone marrow and stimulated for 1 hour with 0, 50 or 200 nM PMA.
Chemokine and cytokine production was measured in the culture supernatant by
multiplex ELISA.
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Age does not affect levels of pro-oxidative or anti-oxidative enzymes in naïve
neutrophils. As studies have shown that age enhances reactive species
generation in human neutrophils, we next wanted to examine whether age
affected the levels of pro-oxidative and anti-oxidative enzymes in murine
neutrophils. We saw no effect of age on the levels of the reactive-producing
enzymes NADPH Oxdiase (NOX2, gp91phox subunit) or inducible nitric oxidase
synthase (iNOS) in isolated bone marrow neutrophils (Figure 11). Similarly, no
significant influence of age was seen on the reactive species neutralizing
enzymes catalase or superoxide dismutase 1 (SOD1) (Figure 12).
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Figure 11. Age does not alter levels of reactive species generating enzymes
in bone marrow neutrophils. Western blot analysis of neutrophils isolated and
purified from the bone marrow of young and aged mice. Primary antibodies
against NOX2 and iNOS were used. Data is presented as a ratio to B-actin
loading control.
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Figure 12. Age does not alter levels of reactive species scavenging
enzymes in bone marrow neutrophils. Western blot analysis of neutrophils
isolated and purified from the bone marrow of young and aged mice. Primary
antibodies against catalase and SOD1 were used. Data is presented as a ratio to
B-actin loading control.
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Age does not affect granularity, size or reactive species content in bone marrow
neutrophils. As protein levels of enzymes do not directly correlate with enzyme
activity, we also measured the production of intracellular reactive species via flow
cytometry using dihydrorhodamine 1,2,3, a fluorescent indicator of reactive
oxygen and nitrogen species. Bone marrow neutrophils were stimulated PMA, a
powerful inflammatory activator, over a range of concentrations (0-200 nM) for 45
minutes before analysis by flow cytometry (Figure 13). No significant difference
in granularity (Figure 13A), size (Figure 13B) or intracellular reactive species
content (Figure 13D) between young and aged neutrophils at any PMA
concentration. A slight increase in the % of reactive species positive neutrophils
in young animals compared to aged animals was seen after stimulation with 200
nM PMA (Figure 13C).
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Figure 13. Age does not affect neutrophil granularity, size or reactive
species content in the bone marrow. Neutrophils from young (3 month) and
aged (22-24 month) mice were isolated from the bone marrow of both hind
femurs. Cells were exposed to increasing concentrations of PMA for 45 minutes,
than analyzed for granularity (A), size (B), reactive species positivity (C) and
intracellular reactive species content (D). **=p<0.01, n=4-5/grp.
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Age augments neutrophil activation and reactive production in circulating
neutrophils. Although we observed no significant differences in reactive species
producing/neutralizing enzymes or intracellular reactive species generation in
bone marrow neutrophils, we hypothesized that aged differences in reactive
species generation may exist in circulating neutrophils. Circulating murine
neutrophils from naïve mice were exposed to 200 nM PMA or PBS control
(Figure 14), followed by flow cytometry to measure side scatter (SSC), forward
scatter (FSC) and intracellular reactive species production (DHR). We found that
neutrophils from aged animals had significantly higher SSC than those from
young animals (Figure 14A), indicating a higher level of granularity/activation. In
addition, aged neutrophils were also found to have significantly greater FSC
compared to young neutrophils, indicating an increase in overall neutrophil size
(Figure 14B). Measurement of intracellular reactive species production showed
that a significantly higher percentage of aged neutrophils were positive for
intracellular reactive species after PMA stimulation (Figure 14C), with a trend
towards increased reactive species content (Figure 14D) compared to young.
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Figure 14. Age enhances markers of neutrophil activation and ROS
production in circulating neutrophils. Neutrophils from the blood of naïve
young and aged mice were stained for neutrophil identification markers
(CD45+/CD11b+/Ly6CInt/Ly6GHi), followed by incubation with or without PMA in
the presence of 1,2,3 DHR to measure changes in (A) neutrophil granularity
(SSC) and (B) neutrophil size (FSC), as well as the percentage of ROS positive
neutrophils (C) and intracellular ROS production (D). *p=<.05, **p=<.01,
***p=<0.001, ****p=<0.0001
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Brain neutrophils from aged animals have higher levels of intracellular reactive
species. Finally, we sought to measure the levels of intracellular reactive species
in brain-infiltrating and bone marrow neutrophils after stroke (Figure 15). Aged
brain neutrophils had significantly higher granularity (Figure 15A) and were
significantly larger (Figure 15B) compared to young neutrophils. No age
difference in the percentage of neutrophils producing reactive species after
stroke was seen in brain or bone marrow neutrophils (Figure 15C). In line with
the results seen previously in circulating neutrophils, brain-infiltrating neutrophils
from aged mice after stroke had significantly higher levels of intracellular reactive
species compared to those from young animals (Figure 15D). Importantly, in
agreement with our results from naïve mouse bone marrow, no age difference in
intracellular ROS content was seen in bone marrow from mice after stroke,
indicating that this age-related enhanced oxidative phenotype may be restricted
to neutrophils that have exited the bone marrow.
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Figure 15. Age augments ROS production in brain-infiltrating neutrophils.
24 hours after stroke, young (3 month) and aged (24 month) mice were
sacrificed, and brains and bone marrow were prepared for flow cytometry.
Intracellular ROS production by neutrophils in the bone marrow and brains of
young and aged stroke mice at 24 hours by dihydrorhodamine (DHR) assay. The
effects of age on (A) neutrophil granularity (SSC) and (B) neutrophil size (FSC),
as well as the percentage of ROS positive neutrophils (C) and intracellular ROS
production (D) were assessed. **p=<.01, ***p=<0.001
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3.5 Discussion
The overall goal of these experiments was to determine whether age
significantly alters pro-inflammatory cytokine or reactive species production in
neutrophils. Furthermore, we wished to determine whether age-related changes
in reactive species production were cell-intrinsic (inherently present in all mature
neutrophils) or dependent on neutrophil mobilization and egress into the systemic
circulation. Neutrophils were found to produce a variety of inflammatory cytokines
and chemokines after inflammatory stimulation, in agreement with existing
literature.144 However, no significant effects of age on inflammatory cytokine or
chemokine production from bone marrow neutrophils were seen.
Under inflammatory conditions, high intracellular levels of neutrophil
reactive species can be released into the extracellular space in an uncontrolled
manner.145 This “spilling” of internal ROS has been implicated in the
pathogenesis of many diseases, including ischemic stroke.146 Next, we examined
whether neutrophils from aged mice produce higher levels of reactive species
than young mice. We found no differences in the levels of reactive speciesgenerating or detoxifying enzymes in bone marrow neutrophils from young and
aged animals. In line with these results, no effect of age was seen on intracellular
reactive species levels in bone marrow neutrophils after ex vivo stimulation with
PMA or in vivo stimulation (ischemic stroke). However, age was found to
significantly increase the activation and percentage of reactive species producing
neutrophils in circulation.
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We then performed flow cytometry on brains from young and aged mice at
24 hours after stroke. Despite no significant difference in the number of braininfiltrating neutrophils, neutrophils from aged animals were found to have
significantly higher intracellular reactive content than neutrophils found in the
brains of young animals. This phenomenon appeared to be specific to the
activated neutrophils within the brain, as a similar age difference was not seen in
neutrophils taken from the bone marrow.
The main weakness of this study was our inability to test the causative
role of age differences in neutrophil-derived ROS in the context of ischemic
stroke. While previous studies have shown that both iNOS and NADPH oxidase
contribute to ischemic stroke pathology in young animals, these enzymes are
expressed in both immune and non-immune cells, preventing a conclusive
connection between neutrophil-derived ROS and stroke outcome.65, 147
Unfortunately, as mature neutrophils are terminally differentiated and easily
activated, they are exceedingly resistant to knockdown via SiRNA or gene
delivery.148 Further experiments utilizing knockout under the control of the newly
discovered, neutrophil-specific MCL-1 gene promoter, may represent a promising
future tool for the study of different oxidative enzymes in age-related neutrophil
reactive species generation.86
In summary, age was not found to affect the ability of bone marrow
derived neutrophils to generate cytokines or reactive species after stimulation.
Further experiments demonstrated that there is an age-dependent increase in
neutrophil reactive species in circulating, but not bone marrow, neutrophils after
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ex vivo inflammatory challenge. Importantly, the same increased oxidative
phenomenon was seen in vivo after ischemic stroke, with brain-infiltrating
neutrophils from aged mice expressing significantly higher levels of intracellular
ROS than those from young animals. These results indicate that age-related
increases in neutrophil oxidative potential may represent one potential
mechanism for the poor outcomes seen in aged animals after stroke (Figure 16).
Interestingly, this enhanced oxidative phenotype was only seen in circulating and
brain-infiltrating neutrophils, indicating that age-related differences may result
from exposure of circulating neutrophils to systemic factors. In Chapter 4, we will
examine the effects of age and stroke on (1) circulating neutrophil phenotype and
(2) levels of neutrophil-activating factors in circulation.
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Figure 16. Graphical abstract of findings from Chapter 3.
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Chapter IV
Aging alters circulating neutrophil phenotype and levels of neutrophilactivating factors after stroke
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Purpose: Previous work determined that the enhanced reactive species
production in aged neutrophils was not intrinsic to bone marrow neutrophils,
indicating that systemic, circulating factors may play a role in age-related
alterations in neutrophil functions. In light of this, we examined the effects of
aging and stroke on circulating neutrophil phenotype and the levels of neutrophilactivating factors in mice and humans.

Experimental Design: Young (3 month) or aged (22-24 month) mice were
subjected to middle cerebral artery occlusion (MCAO) or sham surgery.
Measurements of neutrophil-activating cytokines (IL-6, CXCL1, G-CSF) and flow
cytometry of blood, bone marrow, lungs and spleen was performed in order to
determine how stroke and age affect neutrophil proportions throughout multiple
organ systems. For human studies, serum cytokine measurements of IL-8 and
IL-6 were performed in a cohort of stroke patients and matched controls with
available bio-samples. Whole blood obtained from a subset of stroke patients
was obtained and analyzed by whole transcriptome RNA-sequencing, with subanalysis of differentially upregulated gene pathways in younger vs. older stroke
patients.

Results: Overall, aged animals had significantly higher proportions of neutrophils
in the blood, bone marrow, spleen and lungs. Neutrophils from aged animals had
significantly reduced surface levels of the bone-marrow homing receptor CXCR4
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compared to young neutrophils. Additionally, the post-stroke levels of the CXCR4
ligand CXCL12 was significantly lower in aged animals after stroke. Finally, aged
stroke animals were found to have significantly higher levels of the neutrophil
activating cytokines IL-6, CXCL1 and G-CSF compared their young counterparts.
In human stroke patients, serum cytokine levels of IL-6 and IL-8 were increased
in stroke patients compared to controls, and post-stroke levels of these cytokines
were positively associated with increasing patient age. Stroke induced the
overexpression of neutrophil degranulation pathway genes in human patients,
with a greater upregulation seen in aged stroke patients compared to younger
stroke patients.

Conclusions: Neutrophil proportions in the bone marrow, blood, spleen and
lungs were higher in aged animals compared to those seen in young animals
both at baseline and after ischemic stroke. This neutrophilia may be driven by the
(1) increased levels of neutrophil-activating cytokines (IL-6, CXCL1, G-CSF and
(2) the reduction in factors required for the proper clearance of neutrophils
(CD44, CXCR4, CXCL12) seen in aged animals. In human stroke patients, we
found a similar augmentative effect of stroke and age on the levels of Il-6 and IL8 (the human homolog of CXCL1), as well as an increase in genes involved in
neutrophil degranulation in older stroke patients. This data indicates the
increased magnitude of neutrophil inflammatory activation may be partly driven
by an increase in circulating levels neutrophil-activating cytokines and
chemokines in aged organisms.
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4.2 Introduction
Our previous work has shown that aging has a significant impact on stroke
outcome in mouse models and human patients.96 The impact of aging on brain
physiology and injury is multifactorial, involving systemic changes throughout the
body in addition to alterations in the central nervous system itself.118
Inflammation has been increasingly recognized as a significant driver of agerelated tissue dysfunction, a phenomenon known as “Inflammaging.”119
Inflammaging is characterized by a gradual increase in pro-inflammatory immune
activation as an organism ages, which is believed to be largely driven by cells of
the innate immune system.121 Inflammation is typically caused by tissue injury or
pathogenic infection, and usually resolves once the pro-inflammatory stimulus
has been eliminated.120 During conditions of long-term or excessive inflammatory
response, this resolution can fail, leading to a consistent state of non-productive,
non-resolving inflammation.
Neutrophils are believed to exist in three states; quiescent, primed and
activated.149 Quiescent neutrophils are those described above, which mature and
move quickly through the circulation before returning to the bone marrow, if no
activating stimuli are encountered in the periphery. During highly inflammatory
conditions like injury or infection, neutrophils in circulation will encounter a variety
of activating substances, including cytokines (Il-6, IL-8, G-CSF), complement
factors and DAMPs, that will stimulate them to undergo oxidative burst, NET
extrusion and degranulation.149 These activated neutrophils can then override
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their natural programmed apoptosis and upregulate adhesion molecules on their
surface, enhancing their ability to survive and extravasate into nearby inflamed
tissue.150
The primed state represents an intermediate phenotypic phase between
quiescent and activated, in which no increased oxidative activity is seen.
Nonetheless, stimulation of primed cells results in 10x greater responses than
those seen in quiescent cells.151 It has been suggested that neutrophils can cycle
between quiescent and primed phases, allowing for robust inflammatory
responses when needed, but limiting unnecessary neutrophil activation and
degranulation in order to prevent collateral tissue damage.152 However, in
conditions of chronic inflammation, the majority of circulating neutrophils will
become inappropriately primed by the pro-inflammatory systemic milieu, giving
them the potential to produce unwarranted and excessive tissue damage upon
activation by infection or injury.153
When neutrophils are released from healthy bone marrow, they typically
have a very short life span, with an average half-life of eight hours.68, 154, 155 As
they circulate, neutrophils become exposed to a variety of low-level inflammatory
stimuli, facilitating their shift from quiescent to primed.100 However, in states of
relatively low systemic inflammation, these neutrophils begin to upregulate the
surface CXCR4 receptor, which is involved in the return of neutrophils to the
bone marrow and their apoptosis and clearance by macrophages.156 CD44, a
ligand for E-selectin, also plays a role in the regular clearance of apoptotic, proinflammatory neutrophils from circulation.157
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As organisms age, the systemic milieu shifts towards a pro-inflammatory
environment, characterized by higher circulating levels of inflammatory cytokines
such as IL-6.158 These factors, in addition to others, are capable of neutrophil
priming and activation. As neutrophils have been shown to have an extraordinary
and uniquely plastic phenotype, even short-term exposure to low-grade systemic
inflammaging could be enough to significantly increase the potential for
bystander host tissue damage upon injury-induced activation.159
In this chapter, we examined the effect of age on (1) the organ distribution
of neutrophils after stroke, (2) the surface phenotype of circulating neutrophils
and (3) the circulating levels of neutrophil-activating cytokines in mice and
humans after ischemic stroke.
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3.3 Materials and Methods
Neutrophil Surface Marker Phenotyping Flow Cytometry Panel: Blood was drawn
from naïve young (3 month) and aged (22 month) mice via cardiac puncture and
prepared as above. In addition to neutrophil quantification markers described
above and in Figure S1, cells were also stained with an antibody cocktail
containing four neutrophil surface markers: CD62L-FITC (Biolegend), CXCR4
PerCP-Cy5.5 (Biolegend), CXCR2 PE (Biolegend) and CD44 PE-Dazzle
(Biolegend) and incubated for 30 minutes at RT. After staining, cells were
washed twice and re-suspended in 300ul FACS buffer for analysis on a Cytoflex
S Flow Cytometer (Beckmann Coulter). Data was analyzed as described above.

Serum & Plasma Cytokine Measurements
Blood was drawn from anesthetized young and aged mice 24 hours after sham
or stroke surgery via cardiac puncture. Blood for plasma preparation was drawn
with a 1ml syringe/18g needle pre-coated with heparin (1000U), and collected
into a tube containing 50ul of diluted (200U) heparin. The tube was gently
inverted several times at room temperature before centrifugation at 4°C for 20
minutes at 15,000 RPM. After centrifugation, the top layer of plasma was
removed and stored at -80°C until testing. Chemokine levels were measured in
plasma using the Bio-Plex Pro Mouse Chemokine Assay (Bio-Rad), on a Bio
Plex 200 Luminex System. Two neutrophil chemokines were selected for further
analysis (CXCL2 and CXCL12) by two-way ANOVA.
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In order to best match the serum cytokine data from our human cohort, we
elected to analyze levels of circulating inflammatory cytokines in serum. Blood for
serum preparation was drawn into a clean 1ml syringe/18g needle into a tube
without anti-coagulant, and allowed to clot at room temperature for two hours
before centrifugation and removal of the serum supernatant. Serum was stored
at -80°C until analysis. The levels of IL-6, CXCL1 (the two cytokines identified to
change with age in stroke patients) and G-CSF (an important neutrophil growth
factor) were assessed using the Bio-Plex Pro Mouse Cytokine Assay (Bio-Rad),
on a Bio-Plex 200 Luminex System. Data was analyzed by two-way ANOVA.

Human Serum Cytokine Measurements:
Sample and demographic data collection was conducted at a 868-bed
community based teaching hospital certified as a JCO Comprehensive Stroke
Center (CSC). Blood was drawn from patients (n = 143) and controls (n=17) at
24 ± 6 hours after symptom onset in tubes containing no anticoagulant. Human
subject data for the serum cohort are located in Table S2. Blood was allowed to
clot at room temperature for two hours before centrifugation and removal of the
top layer of serum supernatant. Serum samples were stored at -80°C until use.
Levels of IL-6 and IL-8 were measured in patient serum samples (n=160) by Bio
Plex Pro Human Cytokine Assay (BioRad). All human sample collection was
approved by the Institutional Review Board at Hartford Hospital.
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Statistical Analysis: Differences in two selected serum cytokines (IL-6 and IL-8)
between stroke and control patients were analyzed by Mann-Whitney test. Linear
regression was then used to examine the univariate relationship between stroke
patient age and serum levels of IL-6 and IL-8 at 24 hours. Finally, multivariate
multiple regression analysis to assess the independent relationship between
stroke patient age and serum IL-6 and IL-8 after adjustment for stroke severity
and patient gender as potential confounding variables.

Human Peripheral RNA Collection and Sequencing:
Blood was drawn from patients with middle cerebral artery strokes, cardioembolic
subtype (n = 16) at 24 ± 6 hours after symptom onset. Additional human subject
data for the RNA-sequencing cohort is given in Table S3. Patients were stratified
into older (>75 yrs) and younger (<75 years), and selected to create an
approximate age and stroke severity match between the two groups. For control
studies, blood was also drawn from asymptomatic controls (n=8) recruited at the
University of Connecticut Health Center. All human sample collection was
approved by the Institutional Review Board at Hartford Hospital and the
University of Connecticut Health Center. Blood samples were drawn into
PAXGene tubes (Qiagen) and stored at -80C until use. Samples were thawed
and RNA was extracted by PAXGene blood RNA kit (Qiagen). cDNA libraries
were generated from isolated RNA, followed by RNA-sequencing analysis at the
Center for Genome Innovation (UConn, Storrs, CT) via the Illumina NextSeq 500
Sequencer. The subsequent FASTQ files were genome aligned (Top Hat
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Alignment, Illumina Inc) and analyzed for differential expression (Cufflinks
Assembly & DE, Illumina Inc). Differentially expressed genes underwent FDR
correction (Bejamani-Hochberg) prior to gene pathway analysis (Reactome).
Results reported in this manuscript are limited to pathways with significant q
values following FDR correction, with >2 gene family members represented.
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TIA Control
Patients
64.5 ± 11.13 yr

Ischemic Stroke Patients

Sex (Female, %)

25.0%

47.0%

N

17

143

Age

69.3 ± 14.7 yr

(Mean ± SD)

Table S2. Patient Characteristics for Serum Cytokine (Il-6 and IL-8)
Measurement Studies. The average age, sex composition and n is given for the
patients included in the serum cytokine analysis in Chapter 4. * SD = Standard
Deviation; yr = year
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Stroke Patients (<75 yr)

Stroke Patients (>75 yr)

p-value

N

9

7

Age

85 ± 5.3 yr

64 ± 6.8 yr

<0.0001

Stroke Severity

11 ± 5.2

9.4 ± 5.2

n.s.

MCA Stroke

100%

100%

n.s.

Hypertension

89 %

100 %

n.s.

Heart Disease

50 %

57 %

n.s.

Hyperlipidemia

77 %

71 %

n.s.

Diabetes

42 %

22 %

n.s.

(Mean ± SD)

Co-morbidities

Table S3. Patient Characteristics for RNA-Sequencing Age Analysis.
Demographic table demonstrating differences between our younger (<75 years)
and elderly (>75 years) stroke patients. There are no significant differences in
stroke severity, stroke location or associated co-morbidities between the cohorts.
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3.4 Results
Age differences in neutrophil proportions are seen in multiple organs after
ischemic stroke. Although stroke has been shown to exacerbate the release of
neutrophils from the bone marrow, no published data has yet examined the
effects of aging on stroke-induced neutrophilia. Flow cytometry was conducted in
blood, lungs, bone marrow and spleens from young and aged mice 24 hours
after stroke or sham surgery (Figure 17). By two-way ANOVA, a significant
overall decrease in neutrophil proportions in the bone marrow was seen
(p=0.0039), characteristic of the robust post-stroke release of bone marrow
neutrophils into the circulation (Figure 17A). Interestingly, a significant overall
effect of age was also seen (p=<0.0001), with aged animals displaying relative
increase in neutrophils within the bone marrow compared to young animals
under both sham (p=0.0005) and stroke (p=0.0062) conditions.
As expected, stroke resulted in an overall increase in neutrophil
proportions within peripheral blood (p=<0.0001), with aged animals exhibiting
higher neutrophilia (p=0.0127) than young animals (Figure 17B). However,
despite a significantly higher proportion of neutrophils in the peripheral blood of
aged sham animals compared to young (p=0.05), there was no significant
difference in neutrophil proportions in the blood of young and aged stroke
animals. Stroke increased the percentage of neutrophils in the lungs after
ischemic stroke in both age groups (Figure 17C, p=<0.0001), with an overall
neutrophilic shift seen with aging (p=<0.0004) due to higher neutrophil ratios in
both aged sham (p=0.017) and stroke (p=0.0054) animals compared to their
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young counterparts (Figure 17C). In the spleen, there were also significantly
higher neutrophil proportions after ischemic stroke (p=0.008), with a significant
effect of age (p=0.0097) driven by a significantly higher proportion of neutrophils
in the spleens of aged stroke mice (p=0.015) compared to young stroke mice
(Figure 17D).
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Figure 17. Age and stroke significantly alter neutrophil proportions across
multiple organs. Neutrophils in the bone marrow, blood, lungs and spleen of
young (3 month) or aged (22 month) mice were identified by flow cytometry 24
hours after stroke or sham surgery. Neutrophils were identified as
CD45+/CD11b+/Ly6CInt/Ly6GHi cells. *=p<0.05, **p<0.01, ***=p<0.001,
****p<0.0001. n=3-6/grp.
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Age reduces the expression of receptors required for bone marrow homing and
clearance of circulating neutrophils. In light of the age-related neutrophilia seen
across multiple organ systems in Figure 8, we sought to examine whether age
differences in markers of neutrophil trafficking existed in naïve mice (Figure 18).
CXCR2 and CXCR4 have been shown to control the release of naïve neutrophils
from the bone marrow and their return as exhausted apoptotic neutrophils
respectively. Although there was no significant age difference in CXCR2
expression in blood (Figure 18A), we found that a greater proportion of
neutrophils from young animals expressed the bone-marrow homing CXCR4
receptor (p=0.0003), and that young CXCR4+ neutrophils also had a higher
expression of the receptor per cell (p=0.0021) than aged neutrophils (Figure
18B).
Flow cytometry of blood from naïve young and aged mice revealed that,
while all circulating neutrophils express CD44, those from young mice expressed
significantly higher levels of CD44 on their cell surface (Figure 18C, p=0.0008).
No significant age differences in L-selectin, another cell adhesion molecule found
on neutrophils, were observed (Figure 18D).
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Figure 18. Age reduces expression of receptors required for proper
neutrophil clearance. Neutrophils isolated from the blood of naïve young and
aged mice were stained for neutrophil identification markers
(CD45+/CD11b+/Ly6CInt/Ly6GHi), surface chemokine receptors (CXCR2, CXCR4)
and adhesion molecules (L-selectin, CD44). **p=<.01, ***p=<.001
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Figure 19. Age alters levels of the bone marrow homing chemokine
CXCL12. Plasma was taken from young (3 month) or aged (22 month) old
animals 24 hours following sham or stroke surgery. N=7-12 animals/group.
CXCL12 and CXCL2 were measured via multiplex. Two-way ANOVA was
performed, followed by individual T-Tests with Sidak’s correction. *p=≤.05,
**p=<0.01. A schematic figure of the differential roles of CXCL12 and CXCL2 in
circulating neutrophil homeostasis.
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Age alters levels of the bone marrow homing chemokine CXCL12. As our
previous work showed that neutrophils from aged mice express significantly
lower levels of CXCR4, the receptor for the bone marrow-homing chemokine
CXCL12, we next sought to examine the effects of age and stroke on circulating
levels of this chemokine at 24 hours after stroke (Figure 19). In addition, we also
measured levels of CXCL2, the bone marrow release chemokine responsible for
binding CXCR2 and coordinating the release of neutrophils into the blood. A
significant interaction effect of age and stroke was seen in CXCL12 levels
(p<0.0001), with aged animals showing higher levels of CXCL12 (p=0.05) under
sham conditions, but significantly lower levels of CXCL12 (p=0.006) than young
animals after ischemic stroke. No significant effects of age or stroke were seen
on levels of CXCL2. A schematic figure illustrating the roles of CXCL2 and
CXCL12, and their cognate receptors CXCR2 and CXCR4, is shown (Figure 19).
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Aged mice display altered circulating levels of neutrophil-associated cytokines
after stroke. We then examined serum cytokine levels in young and aged mice
24 hours after ischemic stroke or sham surgery. Levels of IL-6 (a powerful
neutrophil-activating cytokine), CXCL1 (the primary neutrophil chemoattractant,
and G-CSF (a cytokine which stimulates neutrophil production and bone marrow
release) (Figure 20). By two-way ANOVA, there was a significant stroke effect
on serum IL-6 levels (p = <0.0001) in both young and aged animals. A significant
age effect (p = <0.0001) and an interaction effect of age/stroke (p=0.0005) was
also seen, driven by the augmented increase in IL-6 after stroke in aged animals
(p=<0.0001) compared to young animals. Serum levels of CXCL1, a potent
neutrophil chemokine, were found to be significantly elevated in aged animals
over young animals, regardless of sham or stroke status (p=0.05). By two-way
ANOVA, there was a significant increase in G-CSF in stroke animals (p=0.02).
Although the overall effect of age on G-CSF levels was not significant (p=0.06),
there was a significant interaction effect of age and stroke on serum G-CSF
(p=0.05), driven by the significantly higher increase in G-CSF levels in aged
animals after stroke compared to young animals (p=.02).
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Figure 20. Aged mice display altered circulating levels of neutrophilassociated cytokines after stroke. Levels of the neutrophil-associated
cytokines IL-6, CXCL1 and G-CSF in serum from young (3 month) and aged (2022 month) animals 24 hours after sham or stroke surgery. *p≤0.05, **p=<0.01,
***p=<0.001, ****p=<0.0001. Data was analyzed by two-way ANOVA, followed by
Sidak’s multiple comparisons test. n=3/4 mice per group.
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Stroke patient age influences circulating levels of neutrophil-associated
cytokines. In light of our results in mice, we then examined the serum levels of IL6, IL-8 (the human homolog of murine CXCL1) and G-CSF in the serum of
human ischemic stroke patients and controls at 24 hours (Figure 21). As levels
of G-CSF were undetectable in >50% of patients, these results were not
analyzed. Stroke patients were found to have significantly higher levels of serum
IL-6 (stroke: 6.26 ± 9.23 pg/ml, control: 1.96 ± 3.77 pg/ml, p=0.0014) and IL-8
(stroke: 7.27 ± 36.53 pg/ml, control: 3.15 ± 2.47 pg/ml, p=0.0017) compared to
controls (Figure 21A). Looking within the stroke patient population, we found that
increased age was significantly positively associated with higher levels of IL-6
(p=0.015) and IL-8 (p<0.0001) in serum 24 hours after stroke (Figure 21B). In
order to assess the effects of age independently from other confounding
variables (initial stroke severity and patient sex), we performed multivariate
multiple regression analysis (Figure 21C). After adjustment, age remained a
significant independent predictor of higher IL-8 levels after ischemic stroke
(p=0.0008).

Neutrophil degranulation genes are significantly upregulated in older stroke
patients. A homogeneous subset of ischemic stroke patients (n=16) with large
middle cerebral artery strokes of cardioembolic origin was selected for RNAsequencing. Differential gene analysis was examined between all stroke patients
(n=16) and controls (n=8), and between older stroke patients (>75, n=7) and
younger stroke patients (<75, n=9). This age cut-off was selected based on
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previous work in ischemic stroke demonstrating significantly poorer outcome in
elderly patients, defined as >75 years of age.160-163 These patient subgroups
were carefully matched for stroke severity, stroke location and known stroke comorbidities (Table S3). The top upregulated pathways between stroke and
control patients were neutrophil degranulation, immune system and interleukin
signaling (Table 3). In a sub-analysis of the stroke patients, older people were
found to have significant upregulation of genes in both the interferon signaling
and neutrophil degranulation pathways (Table 3).
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Figure 21. Relationship between stroke patient age and serum levels of
neutrophil-activating cytokines. Levels of the inflammatory cytokines IL-6 and
IL-8 were measured in serum from stroke patients or transient ischemic attack
controls 24 hours after stroke onset. A. Comparison of control (n=17) and stroke
(n=143) cytokine levels. B. Linear correlation between ischemic stroke patient
age and serum cytokine levels. C. Multivariate analysis examining the
relationship between patient sex, age, stroke severity and cytokine level.
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Table 3. Effects of stroke and age on circulating gene expression

All Stroke Patients vs. Controls

p-value

FDR

1. Neutrophil degranulation

<0.0001

<0.0001

2. Immune System

<0.0001

0.0002

3. Interleukin Signaling

<0.0001

0.0049

1. Interferon Signaling:

0.0015

0.0392

2. Neutrophil degranulation

0.0024

0.0392

0.0026

0.0392

Older Strokes (>75 yr) vs. Younger Strokes (<75 yr)

3. O2/CO2 Exchange in Erythrocytes
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4.5 Discussion
Age was found to increase neutrophil proportions in the bone marrow,
blood, lung and spleen at baseline in aged animals compared to young.
Additionally, stroke-induced neutrophil proportions in these compartments were
higher in aged animals than in young animals. Taken together, this data
demonstrates that aging results in a neutrophil-skewing of white blood cells
levels throughout the body, an effect that is exacerbated in injury. It is possible
that this neutrophilia is driven by higher levels baseline of circulating
inflammatory cytokines, or “Inflammaging” in aged animals. Neutrophils who
receive consistent low levels of inflammatory activation may resist normal
apoptosis and become primed, allowing them to circulate throughout the body for
longer and augmenting neutrophil pro-inflammatory reactivity after injury.
To examine whether aging was associated with an increase in circulating
cytokines, we assessed the effect of age and ischemic stroke on serum cytokine
levels in mice 24 hours after ischemic injury. We found that aging significantly
increased the circulating levels of CXCL1 in both sham and stroke animals.
Furthermore, we saw an interactive effect of age and stroke on levels of G-CSF
and IL-6 levels, with an augmented stroke-induced increase in these circulating
cytokines in aged animals compared to young animals. These results show that
levels of neutrophil-associated inflammatory cytokines and chemokines are
significantly elevated in aged animals at baseline and after ischemic stroke,
suggesting one potential mechanism for the age-related increase in neutrophil
proportions seen throughout the body.
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Delayed return of neutrophils to the bone marrow may also contribute to
age-associated neutrophilia. To that end, we examined the surface phenotype of
peripheral blood neutrophils from young and aged mice and found that aging is
associated with a significant decrease in CXCR4 and CD44 expression on the
surface of neutrophils. As these surface molecules are responsible for the return
of circulating neutrophils at the end of their life span, these surface changes may
indicate that tired, “primed” neutrophils persist inappropriately in the circulation of
aged animals, enabling faster reactivity and exacerbated tissue damage after
infection or injury.
Taken together, these results suggest that age is associated with an
increase in overall neutrophilia and an increase in neutrophil-activating cytokines
and chemokines, which is exacerbated after ischemic stroke. Neutrophils from
aged animals show an increase in activation both at baseline and after
inflammatory stimulus, but also display a down-regulation of receptors necessary
for clearance of primed cells.
To support our findings in mice, we then examined the association of
ischemic stroke with levels of IL-6 and IL-8 in human patients. Both IL-6 and IL-8
have previously been reported to increase in ischemic stroke patients.164, 165 IL-8,
also known as CXCL8, is the major driver of directed neutrophil chemotaxis in
humans and has been shown to promote neutrophil degranulation and
respiratory burst.166, 167 IL-6 is a pro-inflammatory cytokine that has previously
been shown to accelerate the release of neutrophils from the bone marrow, and
to enhance neutrophil migration towards IL-8.168, 169 In agreement with previous
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reports, we found that IL-6 and IL-8 levels were significantly higher in stroke
patients compared to controls 24 hours after symptom onset. Within stroke
patients, IL-6 and IL-8 were found to be positively associated with increasing
stroke severity. Our data also demonstrates that aging is significantly correlated
with higher levels of IL-6 and IL-8 in stroke patients. As injury severity and patient
sex have both been reported to impact the magnitude of the post-injury
inflammatory response,170, 171 we performed multivariate multiple adjustment
analysis to adjust for sex and stroke severity. Even after the adjustment, aging
remained an independent predictor of higher IL-8 levels in ischemic stroke
patients.
We then wished to investigate whether age altered neutrophil function in
human stroke patients. Unfortunately, as neutrophils cannot be preserved longterm, neutrophil-specific functional analysis with our stored biobank samples was
not possible. However, using whole-blood RNA-sequencing, we were able to
demonstrate that the neutrophil degranulation pathway was the most significantly
upregulated gene expression pathway in a highly homogenous population of
ischemic stroke patients compared to controls. When we divided the ischemic
stroke patient cohort into those <75 years of age and those >75 years of age
(age cut-off determined as described in Section 4.3), we found that the neutrophil
degranulation pathway was significantly more upregulated in older stroke
patients. Our results indicate that, while neutrophil numbers in circulation do
significantly differ based on age, the reactivity of neutrophils in stroke patients
may be enhanced in aged subjects. This data is supported by work done in
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healthy adult humans, which found that neutrophils from healthy aged individuals
show greater degranulation responses to inflammatory stimulation when
compared to those from young individuals, characterized by an increase in
primary granule mobilization, higher neutrophil proteinase activity and increased
neutrophil elastase degradation products.172
There are several limitations in these studies that must be addressed. Due
to the age-skewing of stroke patient demographics in our cohort, we were limited
to comparing the effects of age on neutrophil count in a range of patients from 60
to 100 years of age. However, we feel that these results in human patients
provided a solid platform from which to base a more specific investigation in an
animal model of ischemic stroke.
Nevertheless, our RNA-sequencing results were also limited to the same
age range, but still showed a significant difference in gene expression between
patients from 60-75 years of age and patients > 75 years of age. As non-genetic
stroke in young patients is relatively rare67, these parameters may be best
studied in animal models where surgical induction of stroke can be performed in
both young and aged animals.
An additional weakness in our study is the use of RNA-sequencing in
whole blood, rather than western blot or neutrophil-specific mRNA analysis.
Unfortunately, the ex vivo study of neutrophils in human patients is complex, as
neutrophils do not survive cryopreservation or extensive culture and must be
examined fresh.173 Given the timely and cost-prohibitive process of neutrophil
isolation and the requirement for immediate preparation, we elected to use whole
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blood in our studies. Since white blood cells account for the vast majority of
mRNA in whole blood and neutrophils represent the largest source of RNA in
whole blood preparations from ischemic stroke patients174,
We have shown that age is associated both with poorer stroke outcome in
mice, as well as in humans. Our data demonstrates that aged animals exhibit an
increase in neutrophil proportions in several organs, perhaps driven by an agerelated increase in neutrophil-activating factors (Il-6, CXCL1, G-CSF) and a
decrease in bone-marrow homing factors (CD44, CXCR4/CXCL12) in aged
animals. In addition, we have shown that age is associated with increased levels
of neutrophil-activating cytokines (IL-6 and IL-8) and increased neutrophil
degranulation gene expression in stroke patients (Figure 22).
However, it still remains unknown whether these age-related changes are
a driver of the poor stroke outcomes seen in aging mice. In the next Chapter, we
will utilize a highly specific method of neutrophil depletion to further examine
whether neutrophils are a causative factor in poor stroke outcome in the aged.
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Figure 22. Graphical abstract of findings from Chapter 4.
* indicates results also seen in human ischemic stroke patients.
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Chapter V
Post-stroke neutrophil depletion improves outcome after stroke
in aged mice.
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5.1

Abstract

Purpose: Despite success in experimental animal models of ischemic stroke, all
clinical trials of anti-neutrophil therapies to date have been unsuccessful. All
previously examined anti-neutrophil therapies were relatively non-specific and
were tested only in young animals, potentially contributing to their failure to
effectively translate to improved outcomes in patients. Administration of a
monoclonal antibody to Ly6G can specifically and significantly deplete
neutrophils in mice. We utilized this antibody to examine whether age influences
the pathological role of neutrophils in ischemic stroke, with examination of
mortality rates, behavioral outcomes and long-term tissue atrophy. To assess the
potential influence of sex on therapeutic efficacy, these studies were then
repeated in aged female animals. Follow-up studies investigating the effects of
anti-Ly6G on acute infarct size, hemorrhagic transformation and infection risk
secondary to neutrophil depletion were also performed.

Experimental Design: After dose optimization, anti-Ly6G antibody was given to
young and aged male mice at 4, 24 and 72 hours after stroke. In Cohort 1, the
effects of neutrophil depletion on sub-acute mortality were examined. Cohort 2
examined long-term treatment effects, including functional and histological
outcomes, out to two months after stroke. Finally, we determined the effect of
neutrophil depletion on acute brain tissue injury (72 hours), hemorrhagic
transformation and post-stroke infection risk in aged mice.
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Results: Anti-Ly6G treatment conferred no benefit to young mice, but
significantly improved short-term mortality and behavioral recovery in aged mice.
Anti-Ly6G treatment was also found to be effective in improving behavioral
recovery in female mice. These improved outcomes were independent of
changes in long-term tissue atrophy. Further studies found that, while neutrophil
depletion did not affect peak infarct size or significantly increase bacterial burden
in the lungs at 72 hours, animals receiving anti-Ly6G showed significantly less
secondary hemorrhage into tissue compared to control.

Conclusions: Post-stroke anti-Ly6G treatment significantly improved outcomes
in aged animals only, independent of peak infarct size or long-term tissue
atrophy. A similar protective effect of neutrophil depletion was seen in aged
females and aged males. Neutrophil depletion therapy did not significantly alter
peak infarct size at 3 days post-stroke, but was found to significantly reduce the
degree of hemorrhage in treated animals at 7 days post-stroke. Neutrophil
depletion did not significantly alter post-stroke temperature, nor was it found to
impair bacterial clearance.
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5.2 Introduction.
Work by our lab has previously shown that bone marrow transplantation
between young and aged significantly alters post-stroke outcome (Ritzel et al, in
submission). Aged mice receiving marrow from younger mice had significantly
improved outcomes and decreased neutrophil infiltration into the brain, compared
to aged mice receiving transplants from aged-matched controls. Young animals
transplanted with bone marrow from aged mice were seen to have higher rates of
hemorrhagic transformation, a serious and damaging complication of ischemic
stroke typically seen more often in aged subjects.
As neutrophils have been previously implicated in the process of
hemorrhagic transformation after stroke, we hypothesized that aged neutrophils
may represent the major detrimental factor in aged bone marrow. However, as
bone marrow is comprised of many different cells types, a more specific method
of neutrophil inhibition was required to test this hypothesis.
To date, the question of whether neutrophil infiltration into the brain is a
contributing factor or a consequence of stroke pathology remains largely
unknown.175 Many strategies have been employed to interfere with neutrophil
activation, adhesion and transmigration, with promising animal results, yet none
of the therapies that made it to clinical trials have shown any positive effect on
patient outcome.84, 176-194
One significant flaw in all anti-neutrophil clinical trials to date is that,
despite their intended purpose, none of the drugs chosen were cell-type specific.
Enlimomab, which increased infections and hemorrhagic transformation in
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patients, is an antibody against ICAM-1, an adhesion molecule expressed on all
immune cells and some endothelial cells.176 Due to this non-specificity, the
increased hemorrhage and infection risk may have resulted from endothelial
dysfunction or the global impairment of all immune cells. Similarly, the clinical
trials of UK-276 (anti-CD11b/CD18) and LeukArrest (CD-18) targeted a
component of a surface receptor found on all cells of myeloid origin.178, 179 These
cells include monocytes/microglia/macrophages, which have been shown to be
integral to tissue healing and functional repair after ischemic stroke.24, 195
In addition to maximizing the specificity of anti-neutrophil therapies, it is
critical to realize that neutrophils themselves play several important roles after
injury, including prevention against infection. One tested anti-neutrophil
therapeutic, Enlimomab, was found to increase the likelihood of serious
infections in stroke patients.176, 179 As infection is a major risk factor for poor
outcome after ischemic stroke, it is critical to understand and test the effects of
anti-neutrophil therapeutics on infection risk in patients.196, 197
The timing of anti-neutrophil therapy is also important. Given the narrow
therapeutic window of currently available stroke therapies, it is critical to find
therapies that can benefit stroke patients beyond three hours. Yet many tested
stroke therapies, including anti-neutrophil focused studies, involve depletion or
inhibition before or at the time of stroke onset, significantly reducing the clinical
translatability of the results. In line with this, genetic deletion of neutrophils via
disruption in the MCL-1 gene, are not an ideal method of testing neutrophils as a
therapeutic target in stroke.86
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In light of these results, we elected to choose a method that would allow
us to 1. Deplete neutrophils after stroke (non-genetic based therapy), 2. Achieve
high specificity (to reduce suppression of other, potentially beneficial cell types)
and 3. yield short-term reductions in circulating neutrophils (to limit the risk of
prolonged neutropenia and infection). We selected Anti-Ly6G (clone 1A8), a
monoclonal antibody against the Ly6G receptor on neutrophils, as an ideal
choice for these studies. Anti-Ly6G is highly specific for neutrophils, targeting
them for removal from the circulation and subsequent degradation by
macrophages.198, 199
In these studies, we sought to examine whether neutrophils were a driving
factor in poor outcomes in aged mice after stroke. We hypothesized that antiLy6G would specifically and reversibly deplete neutrophils after ischemic stroke,
and that anti-Ly6G therapy would confer greater benefit to aged animals than
young animals.
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5.3 Materials and Methods
MCAO Stroke Surgery. Animal care and surgery was performed as described in
Chapter 3. In Cohort 1, aged male and female mice were 24 months of age. In
Cohort 2, slightly younger mice were utilized (Cohort 2) to equalize mortality
rates and prevent mortality bias in long-term functional and histological studies.

Cresyl violet atrophy quantification
In cresyl violet cohorts, transcardial perfusion with cold, heparinized PBS was
followed by 4% paraformaldehyde. Brains were collected, fixed in 4% cold
paraformaldehyde for 24 hours, then placed into a 30% sucrose solution to
dehydrate. Following dehydration, brains were frozen and sliced into 30-um
slices on a freezing microtome, with every eighth slice mounted and stained with
cresyl violet for the evaluation of brain atrophy. Digital images were taken and
infarct volumes were measured via computer software (Sigma Scan Pro5) as
previously described.134

Drug Administration. Mice were randomized to receive either 500ug anti-Ly6G
monoclonal antibody (Clone 1A8, BioXCell) or isotype control antibody (Clone
2A3, BioXCell) intraperitoneally (I.P.) at 4, 24 and 48 hours after sham or
ischemic stroke surgery. For the dose determination experiment, an additional
group of mice receiving 200ug of anti-Ly6G antibody was added. Investigators
were blinded to treatment until the conclusion of the studies (at 7 days, or 2
months).
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Neutrophil Depletion Confirmation. Flow cytometry was performed in order to
determine the efficacy of Ly6G tissue penetration and circulating neutrophil
depletion. Sham and stroke mice received 500ug anti-Ly6G or isotype control
antibody at 4, 24 and 48 hours after sham or ischemic stroke surgery. Cheek
bleeds were performed on all mice at 24 hours and 48 hours, and blood was
prepared for flow cytometry. Following red blood cell lysis, cells were stained as
outlined in Chapter 3, and CountBrite (Thermofisher) counting beads were added
to samples before analysis in order to determine absolute neutrophil numbers. In
the treatment group that received anti-Ly6G antibody for neutrophil depletion, the
surface epitope of Ly6G remains highly bound by the depletion antibody,
masking the presence of neutrophils by traditional gating. Therefore, we
developed an alternative gating strategy that did not rely on Ly6G for neutrophil
identification (CD45+/CD11b+/SSCHigh/Ly6CIntermediate). Our alternate gating
strategy is presented in Figure S2. At 72 hours, mice were sacrificed, and blood
was obtained by cardiac puncture. To assess tissue penetration, spleen and
bone marrow were also harvested. All three tissues were prepared for flow
cytometry, and our alternative gating strategy was applied.

Corner Test
The corner test is a measure of integrated sensorimotor function, involving both
sensory stimulation and motor response. The test was performed as described in
Li et al. 2004, with slight modifications.200 The mouse was placed between two
plastic pieces with dimensions of 12 x 24 inches. The two boards were placed at
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an angle of 30° and gradually moved closer to the mouse, encouraging the
subject to move into the created corner. This resulted in stimulation of the
vibrissae on both sides of the mouse’s face, causing the mouse to rear up and
turn back towards the open end. Each mouse was tested in 20 separate trials,
and the percentage of right turns was calculated.

Hanging Wire Test. In this test, mice utilize all four limbs to support their body
weight on a wire-cage elevated 36 inches above a cage containing soft bedding.
The time until the mouse fell was recorded, with an upper limit of 90 seconds.
Mice unable to hang were excluded from the study. For trials involving aged
mice, the average hang time was corrected for weight, to adjust for the weight
variability within the cohort.

Adhesive Removal Test. In this test, a small round adhesive circle measuring
1cm was applied to the left forepaw of a mouse. The mouse was then placed
alone in a clean cage. The time to remove the adhesive sticker was measured,
with an upper limit of 5 minutes.

Acute Infarct Quantification
Aged animals were sacrificed 72 hours post-stroke. Following sacrifice, brains
were removed and flash frozen at 80°C. Brains were then sliced into 2mm
coronal sections, and stained with 1.5% 2,3,5 triphentyltetrazolium (TTC, SigmaAldrich). Sections were fixed in 4% paraformaldehyde overnight before digital
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imaging and infarct measurement (Sigma Scan Pro5) by a blinded investigator as
previously described.134

Lung Bacterial Burden Quantification. Aged mice (22 months) were subjected to
sham or stroke surgery. 72 hours after stroke, mice were sacrificed, and lung
tissue was removed using sterile technique. Tissue was homogenized and plated
on blood agar for 24 hours before assessment of colony-forming units (CFUs).
Bacterial burden was expressed as CFUs per gram of tissue. Anti-neutrophil
depletion in these mice was confirmed by flow cytometry, utilizing the alternative
gating strategy outlined above.
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Figure S2. Alternative gating strategy for anti-Ly6G neutrophil depletion
confirmation (blood). In order to identify neutrophils in the neutrophil depletion
cohort, we utilized an alternative gating strategy. Live, single cells were selected
for CD45 and CD11b expression to classify myeloid cells, followed by
identification of neutrophils as Ly6CIntand SSCHigh cells, with inflammatory
monocytes representing the Ly6CHigh and SSCInt population
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5.4 Results
Post-stroke Anti-Ly6G treatment successfully penetrates tissues and depletes
circulating neutrophils. Although the efficacy of anti-Ly6G in depleting neutrophils
in non-injury conditions has been well characterized, less is known regarding the
ability of anti-Ly6G to significantly deplete neutrophils under conditions of high
neutrophil production and release (e.g. during injury). In order to test whether
anti-Ly6G was capable of producing adequate depletion, both sham and stroke
mice were treated with either 200ug of anti-Ly6G, 500ug of anti-Ly6G or 500ug
isotype control antibody at 4, 24 and 48 hours after stroke (Figure 23). Cheek
bleeds were obtained at 24 and 48 hours, and cardiac puncture and tissue
collection were performed at the 72-hour terminal sacrifice. Flow cytometry
demonstrated that, while 200ug anti-Ly6G was capable of reducing neutrophil
proportions in sham animals (Figure 23A), only 500ug of anti-Ly6G showed
significantly depletion out to 72 hours post-stroke (p=0.0015, Figure 23B). As
neutrophil proportion changes might be driven by alterations in other cell
percentages, we also examined exact neutrophil counts using flow cytometry
counting beads, confirming the proportional results and demonstrating that
absolute neutrophil counts are significantly reduced by anti-Ly6G treatment
(Figure 23C). The penetration of anti-Ly6G into known neutrophil reservoir
tissues was also examined and showed that the vast majority of neutrophils in
the blood, bone marrow and spleen are coated with anti-Ly6G antibody (masking
the subsequent binding of flow-cytometry labeled anti-Ly6G) at 72 hours poststroke (p=<0.0001, Figure 23D).
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Figure 23. Neutrophil depletion efficacy of anti-Ly6G. Young mice were
subjected to sham or stroke MCAO (60 minutes), then treated with either isotype
control antibody, 200ug of anti-Ly6G or 500ug of anti-Ly6G antibody I.P. at 4
hours, 24 hours and 48 hours after stroke. Data was analyzed by two-way
ANOVA, followed by Tukey’s multiple comparisons testing. A. Reduction of
neutrophil proportions in treated sham animals. B. Reduction of neutrophil
proportions in treated stroke animals. C. Absolute neutrophil counts in treated
animals. D. Ly6G median fluorescence intensity in blood, spleen and bone
marrow. n=3-4/grp.
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Post-stroke anti-Ly6G treatment affects mortality in aged animals. Young (3
months) and aged animals (24 months) were treated with 500ug anti-Ly6G
antibody I.P. at 4, 24 and 48 hours post-stroke (Figure 24). No sub-acute
mortality was observed in the young group (Figure 24A). Despite a trend towards
improved mortality in both aged male and aged female animals, no significant
effect of Ly6G was seen when assessed separately (Figure 24C, 24D). When
aged male and female animals were pooled, anti-Ly6G treatment was found to
significantly improve sub-acute mortality at 3 days (Figure 24B, p=0.03).
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Figure 24. Anti-Ly6G treatment improves mortality in aged mice after
stroke. Young (3 months) and aged (24 month) mice were subjected to 60
minute MCAO, followed by treatment with either 500ug anti-Ly6G antibody or
500ug isotype control antibody at 4, 24 and 48 hours post-stroke. A. Mortality in
young animals, n=5/group. B. Mortality in male and female aged animals, n=910/grp. C. Mortality in aged male animals, n=4-5/group. D. Mortality in aged
female animals, n=5/grp.
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Anti-Ly6G treatment improves long-term outcomes in aged, but not young,
animals. As the stroke-induced mortality in 24-month old mice resulted in a
significant survival bias, we then utilized slightly younger mice (21-22 months) to
test the effects of anti-Ly6G on long term outcomes. Using the same treatment
methodology, young (3 month) and aged (21-22 months) mice were subjected to
60 minute MCAO stroke and followed out for two months (Figure 25). Animals
without successful strokes or those with subarachnoid hemorrhage were
excluded from the analysis. In young mice, no significant effects of anti-Ly6G
treatment in long-term mortality (Figure 25A) or neurological deficits (Figure
25B). In line with the neurodeficit data, young animals showed no benefit of antiLy6G treatment on functional outcome after stroke by either corner testing
(Figure 26A) or hang-wire testing (Figure 26B).
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Figure 25. Anti-Ly6G treatment does not improve mortality or neurological
deficit in young mice after stroke. Young (3 month) mice were subjected to 60
minute MCAO, and received either 500ug of anti-Ly6G or 500ug of isotype
control antibody I.P. at 4, 24 and 48 hours after stroke. A. Post stroke mortality
was monitored out to 56 days post-stroke. B. Neurological deficits were
measured at 7, 14, 21, 28 and 56 days post-stroke. N=6-7/group.
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Figure 26. Anti-Ly6G treatment does not affect behavioral recovery after
stroke in young animals. A. Serial corner testing at day 7, 14 and 56 poststroke in young mice after MCAO. B. Hang-wire strength testing in young mice
after MCAO at day 7. N=6-7/group.
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Figure 27. Anti-Ly6G treatment improves gross neurodeficit recovery after
stroke in aged mice. Mortality (A) and neurological deficit score (B) were
assessed in aged (21-22 month) male mice receiving 500ug of anti-Ly6G or
isotype control antibody at 4, 24 and 48 hours after stroke. N=9/group
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Anti-Ly6G treatment improves long-term behavioral outcomes in aged animals.
Next, we examined the effects of anti-Ly6G treatment on long-term outcome in
our aged mice (Figure 27). Despite no differences in long-term mortality (Figure
27A), neutrophil depletion with anti-Ly6G significantly improved gross
neurodeficit recovery after ischemic stroke in aged mice (Figure 27B). Aged
animals, however, demonstrated significant improvement in corner testing at 28
days (Figure 28A), adhesive removal testing at 7 and 28 days (Figure 28B) and
hang wire testing at 14 and 28 days post-stroke (Figure 28C). Y-Maze, Barnes
and Open Field Testing was also performed for both young and aged animals,
but as no significant stroke vs. sham differences were seen in the primary testing
variables (Correct Alternations in Y Maze, Latency to Escape in Barnes Maze,
Percent Time in Center for Open Field Testing), these tests were not considered
for assessment of therapeutic benefit.
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Figure 28. Anti-Ly6G treatment improves behavioral recovery in aged
animals after stroke. Behavioral testing of aged mice receiving anti-Ly6G or
control antibody after ischemic stroke. Behavior was conducted weekly at the
same time each day in a dimly lit, climate-controlled room. n=4-5/group.
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Anti-Ly6G treatment does not affect long-term cerebral atrophy after ischemic
stroke. Improvements in functional outcome after ischemic stroke after
therapeutic delivery can be dependent or independent of gross tissue damage.
As stroke size can significantly change stroke functional outcome and all
secondary inflammatory sequelae, it is critical to determine whether antineutrophil depletion reduces overall direct tissue damage. Cresyl violet staining
for cerebral atrophy in brains taken two months after stroke demonstrated that
anti-Ly6G treatment did not significantly affect brain atrophy in young or aged
mice after ischemic stroke (Figure 29).
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Figure 29. Anti-Ly6G treatment has no effect on long-term cerebral atrophy
after ischemic stroke. Cresyl violet staining of brains taken from young and
aged mice receiving either control antibody or anti-Ly6G treatment two months
after ischemic stroke (n= 4-6/group).
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Anti-Ly6G Improves Outcome in Aged Female Mice
Importantly, sex is also known to play a role in inflammation and outcome
after ischemic stroke. To that end, we also tested the efficacy of anti-Ly6G
treatment on long-term stroke outcomes in female mice (Figure 30). Similar to
aged males, despite no significant difference in long-term mortality (Figure 30A),
aged female mice treated with anti-Ly6G showed significantly improved
neurological deficits by day 14 after stroke, remaining significant at 28 days poststroke (Figure 30B). Further behavioral testing demonstrated a trend towards
improved adhesive removal in anti-Ly6G treated aged females (Figure 30C), and
a significant improvement in hang-wire test in anti-Ly6G treated females at day
28 (Figure 30D).
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Figure 30. Anti-Ly6G treatment improves outcomes in aged female animals
after stroke. Aged female mice received treatment with either 500ug anti-Ly6G
antibody or isotype control I.P. at 4, 24 and 48 hours after stroke. A. Post-stroke
mortality of aged females. B. Neurological deficit measurements in aged female
animals. C. Adhesive testing of aged female animals at 7 days and 28 days poststroke. D. Hang-wire strength testing of aged female animals at 7 days and 28
days post-stroke. E. Atrophy analysis of CV stained slices taken 2 months poststroke. F. Representative CV images for atrophy quantification. N=3-6/group.
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Anti-Ly6G Treatment Results in Significant Neutrophil Reduction in Aged Animals
at 3 Days Post-Stroke. As dose optimization of anti-Ly6G therapy was performed
in young animals, we next sought to confirm that neutrophil depletion via our
treatment paradigm is equally efficacious in aged animals. Flow cytometry of
blood taken from aged male mice 72 hours after ischemic stroke demonstrated
that absolute neutrophil counts were significantly reduced in animals receiving
anti-Ly6G (p=.02, Figure 31).

Anti-Ly6G Treatment Does Not Affect Acute Tissue Injury in Aged Animals
While no differences in tissue atrophy were seen after two months across all
groups, we sought to confirm that our treatment had no effect on the initial injury
size after ischemic stroke. Aged mice were subjected to 60 minute MCAO, and
their brains were harvested at 72 hours (the peak of ischemic injury expansion)
for acute infarct analysis. As shown in Figure 32, anti-Ly6G treatment did not
significantly effect the size of the infarct itself, indicating that neutrophil depletion
therapy likely mediates its beneficial effects in aged animals independently of
direct cerebral tissue damage.
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Figure 31. Anti-Ly6G Treatment Significantly Reduces Neutrophils in Aged
Animals. Aged mice (22 months) were given 500ug anti-Ly6G I.P. at 4, 24 and
48 hours after ischemic stroke. After 72 hours, mice were sacrificed and
neutrophil counts were assessed by flow cytometry. * = p<0.05
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Figure 32. Anti-Ly6G Treatment Does Not Alter Infarct Size in Aged
Animals. Aged mice (22 months) were given 500ug anti-Ly6G I.P. at 4, 24 and
48 hours after ischemic stroke. After 72 hours, mice were sacrificed, and brains
were sectioned and stained with TTC to determine volumetric infarct size.
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Neutrophil depletion significantly reduces the volume hemorrhagic transformation
in aged mice after stroke. As neutrophil depletion did not reduce acute infarct
volume or long-term atrophy post-stroke, we sought to examine other possible
explanations for the improved recovery seen in treated aged mice. Hemorrhagic
transformation after ischemic stroke is a common and serious complication, seen
in both human patients and animal models. Our lab has previous shown that
bone marrow transplantation of aged bone marrow into young mice increases the
incidence of hemorrhagic transformation after stroke. In this experiment, aged
mice were treated with either anti-Ly6G or control antibody after stroke induction.
Seven days post-stroke, mice were sacrificed and brains were perfused and
taken for histology. Volumetric quantification revealed that aged mice treated with
anti-Ly6G showed significantly less hemorrhage into the ischemic tissue after
stroke (Figure 33).
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Figure 33. Neutrophil depletion significantly reduces hemorrhagic
transformation after ischemic stroke. Aged mice received either anti-Ly6G or
control antibody at 4, 24 and 48 hours after ischemic stroke. After seven days,
mice were perfused and brains were removed and sliced. Visible hemorrhage
was quantified by volumetric measurement. *=p<0.05, n=2-3/grp.
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Neutrophil Depletion Does Not Significantly Increase Bacterial Burden in Aged
Animals After Stroke. The leading cause of death in clinical stroke survivors is
infection, secondary to widespread stroke-induced lymphopenia. As neutrophil
depletion with anti-Ly6G is considered an immunosuppressive therapy, we
elected to monitor body temperature and bacterial burden in aged stroke and
sham mice receiving neutrophil depletion therapy (Figure 34). Anti-Ly6G
treatment did not significantly alter body temperature in sham or stroke animals
(Figure 34A). As predicted, bacterial burden in the lung increased significantly
after ischemic stroke, likely secondary to stroke-induced immunosuppression
(p=0.0042, Figure 34B). However, no difference was seen in bacterial burden
between treated and control stroke animals.
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Figure 34. Neutrophil Depletion Does Not Significantly Increase Lung
Bacterial Burden in Aged Animals After Stroke. Aged mice (22 months) were
given 500ug anti-Ly6G I.P. at 4, 24 and 48 hours after ischemic stroke. (A)
Temperature was assessed daily by rectal thermometer (B). After 72 hours, mice
were sacrificed, and lung lobes were harvested and plated to determine bacterial
CFU.
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5.5 Discussion
As predicted, we were able to achieve significant depletion of neutrophils
in the circulation with anti-Ly6G administration. The majority of previous antiLy6G studies were done using 200ug of anti-Ly6G in healthy animals or models
of chronic inflammation. However, as stroke is an acute inflammatory condition
associated with a dramatic upregulation in neutrophil production and release, we
elected to test both the standard dose (200ug) and an elevated dose (500ug)
previously described in an acute inflammatory model.201 Both doses produced
significant reduction of circulating neutrophils up to 48 hours post-stroke.
Ultimately, the 500ug dose was chosen as depletion remained significant out to 3
days, more than 24 hours after the last antibody dose was given. Anti-Ly6G also
demonstrated good tissue penetration in the spleen and bone marrow, ensuring
that neutrophils released from these tissues into circulation could also quickly be
targeted for degradation.
In our pilot cohort, we examined differences in short-term (7 day) mortality
between young (3 month) and aged (24 month) animals. Anti-Ly6G treatment
significantly reduced post-stroke mortality in aged animals. As there was 0%
mortality in the young animal group, mortality effects in young animals could not
be assessed at this timepoint.
In our second, long-term survival cohort, young and aged animals were
followed for two months after stroke. Given the exceedingly high sub-acute
mortality (50% at 2 days) seen in 24-month old animals, we performed the
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second set of experiments using younger mice (21-22 months). This enabled us
to expand the cohort size available for behavior.
No effect of anti-Ly6G on mortality or neurological deficit scores was seen
in young mice out to 2 months post-stroke. Interestingly, mortality rates were
slightly higher in treated animals (34%) compared to control animals (15%),
although this did not reach statistical significance.
In aged animals, no significant effect of anti-Ly6G was observed on longterm mortality out to two months post-stroke. This similarity in mortality rates
enabled us to make comparisons of post-stroke outcome without concern for a
survival bias. Anti-Ly6G was found to improve neurological deficit score recovery,
with significance seen during 30-day testing.
Behavioral tests conducted in young animals showed no significant effect
of anti-Ly6G on recovery in young mice. However, testing in aged animals
revealed a significant improvement in corner test, adhesive test and hang-wire
test with anti-Ly6G treatment. These improvements were most significant in later
timepoints after recovery, indicating that the depletion of neutrophils may be
beneficial via an alteration in the healing process of the aging brain. In further
support of this, no significant differences were observed in atrophy between antiLy6G and control treated aged animals, suggesting that the mechanism of antiLy6G treatment is not directly linked to a decrease in initial tissue damage.
Importantly, age-dependent sex differences in stroke incidence and
outcome exist in clinical populations. As female stroke patients tend to be
significantly older than men at the time of their stroke, elderly women experience
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even higher stroke rates and poorer long-term functional recovery than men.202204

As sex differences in immunity and inflammation have been described in both

humans and animal models, we also examined the efficacy of anti-Ly6G therapy
in aged female mice.205 Similar to aged male mice, we found that female mice
exhibited a significant improvement in neurological deficit scores with anti-Ly6G
treatment. In addition, there was a significant improvement in hang-wire
performance and a trend towards improved sensorimotor function by adhesive
testing at day 28 post-stroke in the treatment group. These results demonstrate
that, despite no significant benefits in young animals, anti-Ly6G depletion of
neutrophils after stroke confers significant benefit to both aged male and female
animals.
Next, to better understand the effects of neutrophil depletion therapy in
aged animals, we confirmed that anti-Ly6G significantly reduces circulating
neutrophil counts in aged animals up to 3 days after ischemic stroke. As
functional recovery tends to show significant improvement at later timepoints,
and no treatment differences were seen in brain atrophy two months after stroke,
we believe this protection may be mediated by an indirect pathway rather than
direct, acute tissue preservation. To confirm our long-term studies showing no
effect of anti-Ly6G on tissue atrophy, we performed acute infarct analysis at 72
hours. These results, showing that anti-Ly6G does not alter the initial infarct size
at peak expansion agrees with our long-term data, which together suggests that
anti-Ly6G mediated protection in aged animals after ischemic stroke is indeed
independent of initial infarct size. To this end, we examined whether anti-Ly6G
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reduces hemorrhagic transformation, which has previously been shown to
significantly worsen stroke outcome in human patients. Our experiment
demonstrated that mice receiving neutrophil depletion therapy exhibited
significantly less hemorrhage at 7 days after stroke compared to the control
group.
Finally, as stroke itself has been shown to increase the risk of infection, it
is important to examine any significant immunosuppressive side effects when
assessing therapeutic benefit. As neutrophils are an important part of immune
protection under normal conditions, we wanted to examine whether neutrophil
depletion after stroke would impair bacterial clearance and increase infection risk
in aged mice. Our results demonstrated that anti-Ly6G treatment had no effect
on temperature or bacterial burden after ischemic stroke, yielding early evidence
that temporary neutrophil depletion in the acute stages of stroke may not put
subjects at undue risk of serious bacterial infections.
Despite this evidence that neutrophils play a greater pathogenic role in
aged animals and that they represent a viable therapeutic target in aging
populations (Figure 35), the mechanism by which aged neutrophils confer
greater damage remains unknown. In the final Chapter of our work, we will
examine potential causes behind the age-specific benefits of neutrophil depletion
in ischemic stroke.
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Figure 35. Graphical abstract of findings from Chapter 5
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6.1 Overall Conclusions
Ischemic stroke is a complex and multifactorial injury that results in
profound and permanent damage to the brain, our most sensitive and essential
organ. As with many leading causes of death, stroke is largely a disease of the
aging population. While the peripheral inflammatory system has been implicated
in secondary damage after ischemic stroke, the complex interplay between
aging, systemic inflammation and tissue injury remains critically understudied.
The work presented in this thesis endeavors to close the gap in knowledge
regarding the effects of aging on neutrophil biology, specifically focusing on how
the neutrophil injury response may undergo a detrimental and destructive shift as
an organism ages.
In Chapter 1, we explored the current state of knowledge regarding the
overwhelming social and economic impact of ischemic stroke on today’s society.
The primary pathologic mechanisms of cerebral ischemia were discussed,
including the significant limitations of currently available treatments for ischemic
stroke. In particular, we highlighted the recent focus on sterile inflammation and
the role of innate immune neutrophils in stroke pathology and outcome.
Neutrophils and their heavy arsenal of damaging immune defenses have been
previously studied as a therapeutic target in ischemic stroke, but numerous
promising animal studies have yielded no effective clinical therapies to date.
We hypothesized that the optimal study of neutrophils in ischemic stroke
pathology would require two additional factors missing from most current
research: (1) the ability to specifically and transiently target neutrophils and (2)
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the examination of therapeutic outcomes in both young and aged animals. In light
of this, we designed our experiments to delineate the effects of age on stroke
outcome in animals and humans, with specific investigation into the role of aging
on neutrophil biology and the implications of age-related changes in neutrophil
function on ischemic stroke pathology and outcome.
In Chapter 2, we confirmed the significant and robust relationship between
advanced age and poor outcomes after ischemic stroke, including the elevated
risk of death or significant disability in older stroke patients. We found that
neutrophil counts increase significantly in the circulation of stroke patients within
24 hours of injury, and that this increase is positively associated with greater
stroke severity. This indicates that neutrophil-targeted therapies may yield
greater benefit in patients experiencing moderate-to-severe strokes, a fact which
should be carefully considered when designing future clinical trials.
We then confirmed that the relationship between advanced age and poor
stroke outcome could be replicated in an experimental model of ischemic stroke,
enabling us to examine the role neutrophils may play in age-related stroke
pathology. Young animals were found to have significantly larger strokes and a
higher degree of edema than their aged counterparts. As seen previously,
despite their smaller strokes, aged animals experienced significantly higher
mortality, poorer weight recovery, greater neurological deficits and impaired
behavioral recovery compared to young animals. As age-related differences in
neutrophil pathogenicity after stroke could result from increased neutrophil (1)
quantity or (2) pro-inflammatory quality, we then used flow cytometry to measure
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the infiltration of neutrophils into the brain of young and aged stroke animals. No
significant difference in the absolute number of brain-infiltrating neutrophils was
seen in aged animals compared to young. In light of this, we focused subsequent
studies on the effects of age on neutrophil pro-inflammatory functions.
In Chapter 3, we examined the effects of age on two potential drivers of
enhanced neutrophil damage after stroke: (1) inflammatory cytokine and
chemokine production and (2) reactive species generation and detoxification. Ex
vivo stimulation of neutrophils from young and aged mice demonstrated that,
although neutrophils release a wide variety of inflammatory cytokines and
chemokines upon stimulation, age does not significantly affect the release of
neutrophil-associated inflammatory factors.
Age was also found to have no influence on the levels of enzymes that
generate (NOX2, iNOS) or detoxify reactive species (SOD1, catalase) in bone
marrow neutrophils by Western Blot. Similarly, age did not alter the ability of
bone marrow neutrophils to produce reactive species upon ex vivo stimulation.
However, we found that age did augment reactive species production in
circulating blood neutrophils. Most importantly, brain-infiltrating neutrophils taken
from aged animals after stroke were found to contain significantly higher levels of
reactive species than those from young animals. In line with our previous
experiments, this phenomenon was found to be specific to activated neutrophils
in the brain, as bone marrow neutrophils from the same stroke animals showed
no significant age difference in reactive species content.
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This data suggested to us that age-related changes in neutrophil function
may be a product of their environment, rather than an innate, cell-intrinsic
change. In Chapter 4, we studied the effects of age on neutrophil-activating
factors in the circulation in both mice and humans after ischemic stroke. We
found that aging results in an increase in neutrophil proportions across multiple
organs, with aged animals showing significantly higher neutrophil increases in
off-target organs (spleen and lungs) after ischemic stroke.
In order to understand the cause of this age-related neutrophil skewing,
we examined the effects of host age on neutrophil chemokine receptors and
circulating levels of their associated ligands. Circulating neutrophils from aged
animals had lower surface levels of the bone-marrow homing receptor CXCR4,
despite similar levels of the circulation-promoting receptor CXCR2. Interestingly,
aged stroke mice had decreased serum levels of the CXCR4 ligand CXCL12
(which promotes bone marrow homing of “exhausted”, hyper-reactive
neutrophils), despite no differences in the levels of CXCL2 (the ligand for CXCR2
that promotes egress of neutrophils from the bone marrow). Levels of surface
CD44, an adhesion molecule important in the normal circadian clearance of
circulating neutrophils, were also significantly lower on neutrophils taken from
aged animals. These results suggest that age-associated neutrophil-skewing in
the blood may result from a failure to remove exhausted, primed neutrophils from
circulation.
As neutrophils with this primed surface phenotype have been shown to
respond quickly and more robustly to inflammatory stimulus, it is possible that
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they may also be capable of greater off-target tissue damage under conditions of
excessive inflammation, including ischemic stroke. It has been suggested that
the abnormal accumulation of primed circulating neutrophils can result from
chronic, low-level “Inflammaging.” Inflammaging is characterized by the higher
baseline levels of inflammatory cytokines (like IL-6) seen in aged organisms
compared to their younger counterparts.
We measured IL-6, CXCL1 (the murine homolog of human IL-8) and GCSF in mice after ischemic stroke. Both age and stroke had a significant
interactive effect on IL-6 and G-CSF levels in mice, with augmented post-stroke
increases seen in aged mice when compared to young mice. Serum levels of
CXCL1, the major chemotactic factor for neutrophils, were found to be
significantly higher in the circulation of aged animals, potentially explaining the
neutrophilia seen in aged animals at baseline and following ischemic stroke.
Taken together, these studies indicate that aging (1) increases the
proportions of neutrophils in the blood, bone marrow, lung and spleen at
baseline, (2) augments post-stroke neutrophilia in off-target end organs, (3)
increases levels of factors (IL-6, CXCL1, G-CSF) involved in neutrophil activation
and entry into circulation and (4) decreases mediators of normal neutrophil
clearance (CXCR4, CD44, CXCL12).
Given our findings in mice, we then examined whether similar increases in
neutrophil-activating cytokines could be observed in human stroke patients. As
predicted, levels of IL-6 and IL-8 were acutely increased in stroke patients
compared to controls. Circulating levels of these cytokines were positively
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associated with increasing patient age, with advanced age remaining a strong
independent predictor of IL-8 levels even after adjustment for confounding
factors.
RNA sequencing analysis of patient whole blood demonstrated that
neutrophil degranulation was the most upregulated gene pathway in stroke
patients compared to controls, and the second-most upregulated gene pathway
in older stroke patients compared to their younger counterparts. These studies
demonstrate that older stroke patients have (1) increased serum levels of
neutrophil-activating cytokines, which are capable of stimulating adhesion,
degranulation and reactive species generation and (2) increased expression of
genes involved in neutrophil degranulation.
In Chapter 5, we performed experiments to assess whether neutrophils
play a causative role in poorer outcome in aged animals after ischemic stroke.
We utilized anti-Ly6G, a monoclonal antibody to the neutrophil-specific Ly6G
receptor, to deplete circulating neutrophils. This paradigm was chosen to
increase clinical translatability and to reduce the likelihood of adverse effects.
First, the antibody can be given specifically post-stroke (unlike a permanent
knockout model, where depletion is lifelong), best mirroring the window in which
a clinical therapeutic agent would be used (4 hours post-injury). Second, the
depletion is transient in nature, allowing circulating levels of neutrophils to return
to normal within three days of the final dose, when the height of neutrophilactivating inflammatory signaling has passed. This transient depletion enabled us
to study the acute effects of neutrophil depletion on stroke outcome while
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reducing the likelihood of excessive immunosuppression and increased infection
risk.
High dose anti-Ly6G was found to significantly deplete neutrophils up to
three days after ischemic stroke in both young and aged mice. The antibody was
found to penetrate into both the spleen and bone marrow, two reservoirs of naïve
neutrophils, ensuring that newly released neutrophils were targeted for clearance
upon entering circulation. In our first cohort, we found that anti-Ly6G treatment
significantly reduced overall acute mortality in aged animals (including both male
and female aged animals, 24 months of age). As there was no mortality in our
young cohort out to 7 days, mortality effects could not be assessed.
Due to the high mortality in the aged control groups from Cohort 1, we
elected not to conduct functional testing in this cohort to prevent the introduction
of survival bias. Instead, we repeated the experiment using slightly younger aged
mice (20 months) and extended the follow-up period to two months.
In young animals, we observed no effect of neutrophil depletion therapy
on mortality, gross neurological deficit and functional outcome after stroke.
However, in aged male animals, we found that neutrophil depletion significantly
improved neurological deficit recovery and functional outcomes out to two
months post-stroke. Similar beneficial effects were seen in aged female mice
receiving neutrophil depletion, with the treatment group exhibiting significantly
better long-term functional recovery compared to control. To our surprise, these
improved outcomes in our aged neutrophil depletion group occurred
independently of changes in long-term tissue atrophy. To confirm that anti-Ly6G
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did not alter the size of tissue injury, we measured acute infarct size at 72 hours
in an additional cohort of aged animals and found that anti-Ly6G had no effect on
infarct size at the time of peak injury expansion.
It has been reported that poor outcome after ischemic stroke can also
result from secondary hemorrhagic transformation into damaged brain tissue. We
have previously observed that aged mice experience higher rates of hemorrhagic
transformation than young mice, and that transplantation of aged bone marrow
into young mice increases the rate of hemorrhagic transformation. In our studies,
neutrophil depletion significantly reduced the degree of hemorrhagic
transformation in aged mice at 7 days post-stroke, indicating that anti-Ly6G
therapy may improve ischemic stroke outcome in aged animals by reducing
neutrophil-mediated damage at the level of the blood-brain-barrier, limiting
hemorrhagic transformation and preserving tissue function.
Ischemic stroke causes profound lymphopenia and lymphoid cell anergy
throughout the body, leaving patients susceptible to a wide variety of infections.
Infection represents the leading cause of death in stroke survivors, particularly in
aged patients who already exhibit baseline immunodeficiency compared with
their younger counterparts. As such, the consequences of immunosuppressant
side effects must be considered when developing potential therapies for stroke
patients. As neutrophils are a critical component of immune protection against
certain pathogens, we sought to determine whether neutrophil depletion impairs
bacterial clearance. Given that ventilator-associated and aspiration pneumonia
are common and serious post-stroke infections, we elected to assess bacterial
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burden in the lungs. As previously reported, stroke significantly increased the
bacterial load within the lungs, but neutrophil depletion treatment did not
exacerbate post-stroke bacterial burden.
As a whole, these experiments suggest that age increase the
pathogenicity of neutrophils in ischemic stroke, independent of alterations in
stroke size. In particular, the improved functional recovery seen in anti-Ly6G
treated animals after ischemic stroke may result from a decrease in neutrophilmediated hemorrhagic transformation. Importantly, neutrophil depletion therapy
does not appear to significantly impair bacterial clearance in stroke animals,
indicating that it may represent a relatively safe form of immunosuppressive
therapy for ischemic stroke.
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6.2 Future Investigations
What drives neutrophil aging? Our data indicate that neutrophil biology changes
with aging, resulting in an exacerbated detrimental phenotype after ischemic
stroke. However, some key questions remain unanswered. First, do specific
cellular processes contribute to the detrimental neutrophil phenotype after
ischemic stroke in aged animals? Our data indicates that reactive species
production in neutrophils from aged animals is heightened, indicating that
reactive species as a strong candidate for increased age-related neutrophil
pathogenicity in ischemic stroke. To that end, future experiments (described
below) should investigate whether reactive oxygen species production or reactive
nitrogen species production are necessary for the detrimental phenotype of aged
neutrophils. In addition to reactive species production, neutrophils also engage in
several other critical defensive processes, including the generation of NETs and
the release of antimicrobial and degradative granule proteins. Further
experiments should determine whether NET production, or key damaging
granule proteins, are critical to the heightened detrimental role of neutrophils
(described below). Although neutrophils are capable of phagocytosis, it is
considered a minor function, and does not represent a likely cause of age-related
neutrophil pathogenicity. The second important question to be answered is
whether age-related differences are inherent to the cells themselves, or a product
of the aging environment. As discussed below, future experiments using bone
marrow chimera mice will be designed to determine whether age-related
differences in neutrophil function are intrinsic (present during neutrophil
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differentiation and maturation) or extrinsic (the result of phenotypic changes in
neutrophils secondary to an aging environmental milieu). If changes to neutrophil
phenotype with age are found to be neutrophil intrinsic (present in naïve
neutrophils and progenitor cells from aged animals), a third set of future
directions will be explored. In these experiments,
Third, we will investigate whether changes in neutrophil trafficking,
mobilization and clearance play a role in heightened neutrophil pathogenicity with
age. While intrinsic neutrophil pathogenic processes may play a critical role in the
detrimental phenotype seen in ischemic stroke, it is also possible that a loss of
regulation at the level of neutrophil release and clearance, perhaps secondary to
impaired macrophage function, might drive the excessive neutrophil response
seen after injury in aged animals. To this end, future experiments will investigate
the effect of age on neutrophil trafficking, mobilization and clearance, and
interrogate several factors identified in this thesis work that may contribute to
altered neutrophil movement and regulation, as described below (CXCL1, IL-6,
G-CSF). Fourth, we will determine whether common co-morbidities seen in aged
mice and humans, including hyperlipidemia and hyperglycemia, specifically
contribute to the detrimental neutrophil phenotype in ischemic stroke.
Our data demonstrates clear age-related changes in neutrophil
phenotype, and their contribution to ischemic stroke pathology. It remains
unknown whether specific neutrophil functions (RS production, NETs, granule
proteins) and/or altered neutrophil behavior (aberrant trafficking, excessive
mobilization, impaired clearance) underlie this difference. Furthermore, it remains
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unknown whether these changes are intrinsic to neutrophils and their progenitor
cells, or a result of the exposure of neutrophils to a heightened inflammatory
environment in the aged host, including exposure to high glucose and lipid levels.
The experiments described below aim to elucidate the answers to these
questions.

Elucidating the Mechanism and Impact of Augmented Neutrophil-Derived
Reactive Species Production in Aged Animals After Stroke.
Our studies suggest that neutrophils from aged animals are primed to
produce augmented levels of reactive species compared to those from young
animals. Previous studies in animals have found that neutrophils are a major
source of reactive species in the brain during ischemia and reperfusion.84, 206
Reactive species are believed to cause further brain injury via damage to
cerebral vessels, glial cells and neurons, and are believed to contribute
significantly to secondary hemorrhagic transformation.8 Yet despite the success
of free-radical scavenging agents in animal models of ischemic stroke188, 190, 207,
208

, these non-specific pharmacologic agents have failed to improve outcome in

ischemic stroke patients.186, 189
The failure of these agents, which involve global inhibition of free radicals,
is likely due to two factors. First, pharmacologic inhibition of free radicals results
in their global suppression, leading to significant non-specificity. While neutrophilderived reactive species may play damaging roles in ischemic injury, free
radicals are involved in many normal physiological processes in many cell types,
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including the propagation of intracellular signaling. Second, the pre-clinical
therapeutic studies only utilized young animals, despite the fact that stroke is a
disease of age. One clinical study specifically highlighted the use of young,
healthy animals in pre-clinical studies as a potential reason for the therapeutic
failure of radical scavenging therapies in elderly ischemic stroke patients.186, 189
In the context of ischemic stroke, we found that depletion of neutrophils
after injury onset resulted in improved functional recovery in aged, but not young
animals. In addition, age-related secondary hemorrhagic transformation was
attenuated in aged animals receiving neutrophil depletion therapy. Our results
indicate that there is a uniquely detrimental role of neutrophils in aged subjects
after stroke. As neutrophils from aged mice were found to produce significantly
higher levels of reactive species than neutrophils from young mice, and reactive
species production has been linked to hemorrhagic transformation and tissue
damage in ischemic stroke, we hypothesized that age-driven alterations in
neutrophil reactive species production may contribute to the poorer outcomes
seen in aged animals after ischemic stroke.
However, whether neutrophil specific reactive species production is a
causative factor in these poor outcomes remains unknown. In order to address
this, future studies involving neutrophil-specific knockout of key reactive speciesgenerating enzymes, including neutrophil NADPH oxidase and inducible nitric
oxide synthase, should be conducted (Figure 36).
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Figure 36. Schematic representation of future directions investigating whether
neutrophil reactive species generation is specifically responsible for the poorer
outcomes seen in aged animals after ischemic stroke.
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Neutrophil NADPH Oxidase. The generation of superoxide (O2-) radicals
after ischemic stroke is believed to contribute significantly to tissue pathology
after ischemic stroke.209 The multi-subunit NADPH oxidase is responsible for
generating superoxide within neutrophils, with NOX2 serving as the catalytic
subunit.210 Global inhibition of NOX2 in young animals by pharmacologic
(apocyanin) or permanent genetic methods has been shown to reduce stroke
size and neutrophil infiltration.211, 212 In order to understand whether the
generation of reactive oxygen species by NADPH oxidase contributes to the
poorer outcomes seen in aged stroke animals, improved genetic models are
needed.
Given the importance of NADPH oxidase in normal intracellular signaling
across a variety of cells, the ideal genetic model would allow knockout of NOX2
specifically in neutrophils. As the timing of neutrophil infiltration and
pathophysiology may differ between young and aged mice, this model should
also be inducible, rather than permanent. Use of an inducible knockout, such as
the Tetracycline-On system, will allow the study of neutrophil-derived reactive
species in both the acute, sub-acute and chronic phases of post-stroke
inflammation. Neutrophil-specific gene targeting can be accomplished via a
MRP8 (S100A8) transgene, which was recently shown to be result in highly
specific gene knockout in neutrophils.213
To create a neutrophil-specific, inducible knockout system, mice carrying
three component alleles are required: (1) a Tet-On tetracycline-dependent
transcription factor (rtTA) under the regulation of the neutrophil-specific MRP8,
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(2) a TetO-Cre transgene and (3) the floxed NOX2 allele. Treatment with
doxycycline will result in binding of the rtTA protein to the TetO sequence,
activating the Cre and resulting in knockout of NOX specifically in neutrophils.214
As neutrophils take approximately 4-6 days to mature, experiments to confirm the
efficacy and timing of doxycycline-induced NOX2 knockout should be performed
to determine the dosing schedule needed to achieve neutrophil-specific NOX2
inhibition during the acute (0-3 days), sub-acute (4-7 days) and chronic (7-28
days) periods post-stroke.
After optimization, young (3 month) and aged (20-22 month) transgenic
mice will be treated with or without doxycycline, and subjected to MCAO stroke
(Figure 37). If our hypothesis is correct, acute inhibition of neutrophil NOX2 by
doxycycline treatment (and the downstream suppression of neutrophil reactive
oxygen species generation) should significantly improve functional recovery
specifically in aged mice, with little effect in young mice. Secondary experiments
should be performed using anti-Ly6G neutrophil depleting antibody to determine
whether NOX2 inhibition and neutrophil depletion have synergistic effects, no
additive effect or antagonistic effects on outcome in aged mice after stroke.
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Figure 37. Schematic representation of strategy to evaluate the role of
specific neutrophil functions in the enhanced pathogenicity of neutrophils in aged
animals after stroke. In this example, either NOX2 (NADPH Oxidase) or iNOS
(inducible nitric oxide synthase) are temporarily inhibited in a Tet-On system by
the delivery of doxycycline prior to ischemic stroke. These experiments will
evaluate whether the production of neutrophil reactive oxygen species (ROS),
reactive nitrogen species (RNS) or both are directly involved in the enhanced
neutrophil-mediated damage seen in aged animals after stroke.
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Inducible Nitric Oxide Synthase. While reactive oxygen species generation
via NOX2 represent a powerful mechanism of reactive species generation after
stroke, reactive nitrogen species (RNS) are also believed to play a significant role
in ischemic stroke pathology.215 Two of the most common RNS are nitric oxide
(NO) and peroxynitrite (ONOO-), both of which have been found at high
concentrations within the brain after stroke.215 Three different isoforms of nitric
oxide synthase (NOS) can produces NO. Endothelial NOS (eNOS) produces
consistent, low levels of NO that help to regulate normal vascular physiology, and
the constitutive expression of neuron-derived NOS (nNOS) in the brain serves to
regulate synaptic plasticity and local blood flow.216
Inducible NOS (iNOS), which is highly expressed in immune cells upon
inflammatory stimulation, is believed to play a significant role in injury after brain
ischemia. iNOS produces very high levels of NO, which can then combine with
superoxide (O2-) to produce highly reactive peroxynitrite (ONOO-). High levels of
these RNS are neurotoxic, resulting in both direct cell death and further
exacerbation of blood-brain-barrier breakdown.215 Global genetic or
pharmacologic inhibition of iNOS has previously been shown to reduce tissue
injury and improve outcome in rodent models of ischemic stroke.62, 217
As these methods resulted in global loss of iNOS function and were
conducted in young animals, the contribution of neutrophil-derived iNOS to stroke
pathology in clinically-relevant aged animals remains unknown. As our data
showed that neutrophils from aged animals produce significantly higher levels of
intracellular reactive species (including both RNS and ROS), it is possible that
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this phenomenon is driven in part by changes in iNOS function with age. To test
whether iNOS contributes to the age-related increase in neutrophil reactive
species production and pathogenicity after ischemic stroke, a doxycyclineinducible, neutrophil-specific knockout of iNOS must be used (methods and
experimental plan as described previously).

The Effects of Age on Other Pathogenic Neutrophil Functions
In addition to an increase in reactive species production, age-related
changes in the production of neutrophil extracellular traps (NETs) and the
composition of neutrophil granule proteins may contribute to poorer stroke
outcomes in aged animals (Figure 38). Although not considered within the scope
of this study, understanding the effects of age on these neutrophil functions may
provide further insight into the exacerbated neutrophil pathogenicity seen in our
aged animals.
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Figure 38. Schematic representation of future directions investigating whether (1)
neutrophil NETosis and/or (2) degradative neutrophil granule proteins specifically
contribute to the poorer outcomes seen in aged animals after ischemic stroke.

167

NETosis. During conditions of strong inflammatory stimulus, including
infection and major tissue injury, neutrophils can undergo a specialized form of
death known as NETosis. During this process, neutrophils cast out their nuclear
chromatin, which is studded with histones and anti-microbial proteins. NETs have
been shown to have protective functions during infection, via their ability to trap
and damage microorganisms. However, NETosis has also been observed under
conditions of sterile injury, including ischemic stroke, where it is thought to
contribute to the propagation of inflammation and further tissue injury. Given the
relationship between high intracellular RS levels and increased NETosis, future
studies should examine the effects of age on neutrophil NET production and
NET-mediated damage.
Several methods should be utilized in order to fully assess whether age
has significant effects on neutrophil NET production. Neutrophils must first be
isolated from the bone marrow and circulation of young and aged animals, as
described in our previous experiments. Cells are then stimulated with PMA for
four hours, to induce cell death and the release of neutrophil NETs, neutrophil
chromatin studded with neutrophil elastase (NE) and other granule proteins
(NETs).218, 219 The presence and structure of NETs can then be confirmed by
microscopy.220-222 As immunohistochemistry can be difficult to quantify, two
alternative methods can then be utilized to examine potential quantitative
differences in NET production between young and aged neutrophils.
First, the activity and protein levels of NET component proteins,
particularly NE, can be used as surrogate NET markers. In this assay, soluble
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NE is washed away after 4 hours of ex vivo stimulation with PMA, and bound
NETs are dissociated by the addition of S7 nuclease. The activity of NE released
from dissociated NETs can then be assessed by the addition of a substrate,
which will produce a colorimetric produce after cleavage by NE.218, 219 These
samples can also be run in an ELISA for NE, to yield information about the
quantity of NE.223 NET formation can also be quantified by flow cytometry by costaining for extracellular DNA and myeloperoxidase (MPO), a strategy which has
been shown to correlate well with results obtained from established microscopybased methods.224
Using the above methods, a timecourse of NET formation (from 0 – 4
hours of stimulation) and dosage response (from 0 – 200 nM PMA) should be
performed on neutrophils from young and aged mice to determine whether (1)
aged neutrophils produce greater quantities of NETs and (2) whether aged
neutrophils die and produce NETs at lower levels of stimulation or duration
compared to young animals. If age-related differences in NET formation are
observed, the next step will be to determine whether age-related differences in
neutrophil NET formation contribute to the poor outcomes seen in aged animals.
Stroke outcomes can be studied in young and aged transgenic mice (as
previously described), using a mouse model with an inducible, neutrophil-specific
knockout of mouse peptidylarginine deiminase 4 (PAD4), a protein that has been
demonstrated to be necessary for NETosis.225
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Neutrophil Granule Contents. In addition to the release of reactive species
and NETs, neutrophils also release several types of granules upon inflammatory
stimulation. As previously discussed, these granules contain a wide variety of
anti-microbial and inflammatory response proteins.226 Several of these proteins,
including haptoglobin and lactoferrin, help to control stroke-induced inflammation
by binding and sequestering inflammatory cytokines and toxic factors.227, 228
Other factors, including the tissue degenerating enzymes MMP-9 and NE,
contribute to further tissue damage and inflammation after ischemic stroke.229, 230
MMP-9, a degradative enzyme expressed at high levels in neutrophils, is
of particular interest in ischemic stroke as it has been linked to disruption of the
blood brain barrier and secondary hemorrhagic transformation.231 As our lab has
seen a higher rate of hemorrhagic transformation in aged animals compared to
young, and work previously described in this dissertation found a reduction in
hemorrhagic transformation after treatment with anti-Ly6G, further investigation
into age differences in neutrophil MMP-9 expression and activity is warranted. In
addition, to determine the potential contribution of MMP-9 to the poor stroke
outcomes seen in aged animals, our inducible, neutrophil-specific knockout
model can be employed to determine whether loss of MMP-9 is preferentially
beneficial in aged mice after stroke. A similar strategy can be employed to
examine the contribution of other detrimental neutrophil granule proteins,
including NE, proteinase-3, cathepsin G and myeloperoxidase.232
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Determining Whether Age-Related Neutrophil Pathogenicity Is an Intrinsic (CellInherent) or Extrinsic (Environmental) Phenomenon.
Neutrophil Intrinsic vs. Environmental Factors. Our data (Chapter 5)
suggests that age increases the pathogenic impact of neutrophils after ischemic
stroke. However, it is important to note that the increase in reactive species
production seen in aged neutrophils compared to young was only observed in
circulating and brain-infiltrating neutrophils, with no significant age differences
seen in cells derived from the bone marrow. These results suggest that
enhanced reactive-species production may not be inherent to aged neutrophils,
but rather a product of altered neutrophil mobilizing and activating factors in the
aged circulation.
To that end, we can perform bone marrow chimera (BMC) experiments in
order to determine whether the age-related increase in neutrophil RS production
(and other neutrophil functions, as described above) is cell intrinsic or dependent
on the aged host milieu. For these experiments, young and aged mice will be
irradiated before reconstitution with bone marrow cells from young or aged donor
(GFP+). After eight weeks, immune system reconstitution can be confirmed by
cheek bleed flow cytometry, to check for the presence of circulating GFP+ donorderived immune cells in the recipient mice. Four experimental groups will be
generated: Young Recipient-Young Donor (YR-YD), Young Recipient-Aged
Donor (YR-AD), Aged Recipient-Young Donor (AR-YD) and Aged RecipientAged Donor (AR-AD). Each group will be subjected to stroke or sham surgery,
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and will be randomized to receive anti-Ly6G treatment or isotype control at 4, 24
and 48 hours post-stroke.
If the age-related increase in neutrophil RS and pathogenicity in ischemic
stroke are cell intrinsic, we would expect to see that both groups of animals with
age-derived neutrophils (AR-AD and YR-AD) would have higher levels of RS in
brain-infiltrating neutrophils after ischemic stroke. In addition, we would expect
that both AR-AD mice and YR-AD mice would have poorer functional outcomes
than their counterparts receiving young bone marrow (AR-YD and YR-YD,
respectively). We would expect that this effect would be ameliorated in mice
receiving neutrophil depletion therapy with anti-Ly6G, as the damaging effects of
age-derived neutrophils would be suppressed.
Conversely, if the age-related increase in neutrophils RS and
pathogenicity in ischemic stroke are dependent on the surrounding proinflammatory milieu of the aged host, we would expect to see that both groups of
aged animals (AR-AD and AR-YD) would have higher brain-infiltrating neutrophil
RS levels than young animals (YR-AD, YR-YD). Furthermore, we would expect
to see poorer outcomes in both aged groups compared to their young
counterparts (AR-YD worse than YR-YD, AR-AD worse than AR-YD), and an
improvement in behavioral recovery in both aged mouse groups after treatment
with anti-Ly6G, which would be absent in the young mouse groups.
A third possibility exists, in which both age-related intrinsic neutrophil
changes and alterations in the aging milieu contribute to neutrophil pathogenicity
after ischemic stroke. In that case, we would expect to see that aged mice
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receiving aged bone marrow (AR-AD) would have the highest levels of braininfiltrating neutrophil RS, the poorest stroke outcomes, and the best response to
anti-Ly6G treatment out of the four groups. AR-YD mice, which lack aged
neutrophils but retain an aged inflammatory milieu, would show a milder RS
phenotype and better outcomes than AR-AD. Young mice receiving aged marrow
(YR-AD) would show higher levels of neutrophil RS and poorer outcomes than
YR-YD mice, which would be expected to have the lowest levels of RS in brain
infiltrating neutrophils, the best overall stroke outcomes and receive minimal
benefit from anti-Ly6G therapy.
If the aged host milieu is shown to be either necessary or sufficient for
exacerbated neutrophil reactive species generation and pathogenicity after
ischemic stroke (discussed above), our work has already highlighted several
candidate circulating factors for age-related alterations in neutrophil pathogenicity
that will warrant further examination. If our experiments indicate that age-related
enhancement of neutrophil pathogenic functions and disease pathogenicity are
not a result of the aging environment, we must then explore the possibility that
these changes are cell- intrinsic. Several theories on the cause of cellular aging
have been proposed, which can be largely split into two categories – those that
define aging as a programmed cellular process, and those that hypothesize that
aging results from the accumulation of cellular damage over time.
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Investigating Excessive Neutrophil Mobilization, Hyperactivation and Delayed
Clearance in Aged Animals
Neutrophil Mobilization. During a profound systemic inflammatory insult
like ischemic stroke, neutrophils are released en masse from the bone marrow
into the circulation. In concert, high levels of inflammatory cytokines (TNF-α, IL1β, IL-6) and growth factors (G-CSF) upregulate the new generation of bone
marrow neutrophils and suppress the apoptosis of circulating neutrophils to meet
the increased demand.233 Down-regulation of the bone marrow retention
chemokine CXCL12 coupled with upregulation of CXCL1 and CXCL2 promote
the release of neutrophils into the blood.234, 235 Due to the suppression of
neutrophil apoptosis by factors like IL-6 and G-CSF and the decrease in bone
marrow retention signals (CXCL12/CXCR4), the negative feedback control on
neutrophil production is circumvented. This breakdown in neutrophil homeostasis
is thought to benefit organisms during times of infection, where large numbers of
neutrophils are required for protection.
However, during conditions of extreme systemic inflammation like
ischemic stroke, these processes are thought to cause severe functional
abnormalities in neutrophil biology that both impair their ability to fight infection
and result in their inappropriate and sustained recruitment into tissue, resulting in
significant secondary damage.236 In this body of work, we found that bone
marrow retention signals (CXCL12/CXCR4) were significantly decreased in aged
animals. These findings highlight the potential utility of chemotactic pathways as
targets for ischemic stroke therapy in aged patients.
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Age-related decreases in normal return of primed neutrophils to the bone
marrow may contribute to the (1) hyperactive neutrophil phenotypes and (2) the
pathogenicity of neutrophils in aged animals during ischemic stroke observed in
this study. To that end, we can examine whether promoting neutrophil return to
the bone marrow (via agonistic engagement of the neutrophil bone marrow return
receptor CXCR4,237 antagonistic engagement of the neutrophil bone marrow
escape receptor CXCR2,238 or exogenous addition of the bone marrow return
chemokine CXCL12239 ) preferentially improves outcomes in aged animals after
ischemic stroke.
Neutrophil Priming & Hyperactivation. It is interesting to note that our data
suggests that the stroke-induced increase in IL-6 and IL-8/CXCL1 (in mice and
humans) and G-CSF (in mice) is augmented in the circulation of aged subjects.
As reactive species hyperactivity was seen in circulating and brain-infiltrating
neutrophils, but not present in bone marrow neutrophils, we hypothesized that
the elevated levels of IL-6, CXCL1 and G-CSF found in the circulation of aged
mice could prime neutrophils, enabling them to achieve higher levels of activation
and reactive species production upon inflammatory stimulus (ex vivo PMA or in
vivo ischemic stroke). In the future, a combination of in vivo and in vitro
experiments may help to elucidate the role of these factors in the hyperactive
reactive species phenotype of neutrophils in aged mice. Neutrophils isolated from
the bone marrow of young and aged mice can be cultured with increasing
amounts of IL-6, CXCL1 and G-CSF, and their reactive oxygen species
production, NETosis and granule protein release can be assessed.
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If our hypothesis is correct, and the hyperactivation seen in aged
circulating neutrophils is due to the greater baseline levels of these factors in
aged mice, we would expect to see increases in both young and aged neutrophil
inflammatory responses after the addition of these factors. If these selected
targets do not significantly increase neutrophil activation, we can then perform
similar experiments using whole serum from young and aged mice (with or
without stroke). If serum from aged animals increases neutrophil activation
significantly compared to young animal serum, we can then perform screening
assays (multiplex ELISA, proteomics analysis) to identify other potential serum
factors driving the age-related increase in neutrophil activity.
If the serum factors that contribute to neutrophil hyperactivation in aged
animals are identified, we must then determine whether these neutrophilactivating substances play a mechanistic role in the heightened pathogenicity of
aged neutrophils in ischemic stroke. To that end, we can again use our inducible,
neutrophil specific knockout model to inhibit expression of the receptors for each
candidate factor (IL-6R for IL-6, CXCR2 for CXCL1 and G-CSF Receptor for GCSF, etc.). These experiments will allow us to determine whether the detrimental
role of neutrophils in aged animals after stroke is dependent on the ability of
neutrophils to respond to these factors. For more specific control over the timing
of inhibition and to mimic future translational therapy, we can also utilize
pharmacologic approaches to block these pathways,240-242 although this will
result in less specific inhibition that may affect cells other than neutrophils.
Excitingly, our lab has recently found that blockade of the IL-6 receptor
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significantly improves outcome in aged male and female mice after stroke (data
unpublished). Future experiments will examine whether the protective effect of
IL-6R blockade is mediated in part by its effects on neutrophil function.

Off-Target Chemotaxis. In other severe inflammatory injuries, such as
sepsis, neutrophils have been reported to undergo “neutrophil paralysis”, during
which their chemotaxis and adhesion molecule expression becomes
deranged.243, 244 Rather than trafficking to the target tissue, neutrophils infiltrate
the microvasculature of sensitive organs like the lung, liver and kidneys,
mediating significant off-target tissue damage.245 As our neutrophil depletion
studies found no significant effect on brain atrophy itself, it is possible that the
improved outcome in aged mice was due to the suppression of deleterious offtarget organ damage. To this end, future experiments should analyze both the
effects of age on neutrophil chemotaxis after stroke and the potential benefits of
neutrophil depletion on off-target organ damage.

Neutrophil Clearance. As neutrophils themselves are short lived, they are
hypothesized to undergo apoptosis within the injury site, after which they are
cleared by macrophages.246 The purpose of this process, known as efferocytosis,
is believed to be two-fold: to limit the noxious potential of neutrophil inflammatory
functions and to stimulate the phenotypic shift of macrophage-like cells towards a
pro-resolving, anti-inflammatory phenotype.247 Future studies should examine the
impact of neutrophil depletion on the phenotype of the subsequent immune
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response, particularly the phenotype of macrophages and monocytes
(measureable by flow cytometry). As these cells have been shown to be integral
to post-stroke tissue repair, it is possible that the high levels of efferocytosis
stimulated in neutrophil depleted animals (as anti-Ly6G tagged neutrophils are
cleared by macrophages) may favor a shift towards anti-inflammatory, prorestorative macrophage phenotypes within the brain.

Neutrophils and Age-Related Stroke Comorbidities
One additional important factor to consider is that our aged mice tend to
weigh significantly more than our young mice, driven largely by an increase in
abdominal adipose tissue. Our lab has previously shown that these older mice
have a higher incidence of hyperlipidemia and hyperglycemia than young mice.
These chronic conditions, which are also more common in aged patients, could
potentially contribute to the enhanced pathogenicity and pro-oxidative phenotype
of neutrophils we see in our aged mice.
Hyperlipidemia and hyperglycemia have been reported to contribute to
chronic and excessive neutrophil activation, which is believed to further
exacerbate tissue damage in chronic inflammatory conditions.98 Hyperglycemia,
which often occurs with aging in both mice and humans, has been shown to
increase neutrophil numbers in circulation and within wound sites, and to
augment neutrophil ROS production, cytokine secretion and NETosis in
patients.67, 248, 249
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Hyperlipidemia and obesity have been shown to result in a build-up of lipid
metabolites and secondary inflammation throughout the body.250-253 Studies have
previously shown that obesity is correlated with increased production of
neutrophil-derived ROS, including superoxide.254-256 Recent work by Roberts et
al. found that neutrophils from obese patients release significantly higher levels
of ROS compared to neutrophils from controlled patients, which could be partially
reduced by significant weight loss.257
In light of the undeniable association between age and neutrophilactivating comorbidities in human patients, future experimental work should
assess whether conditions such as hyperlipidemia and hyperglycemia are (1)
necessary and (2) sufficient for age-related increases in neutrophil pathogenicity
after ischemic stroke. Fascinatingly, recent work in a mouse model has shown
that induction of acute hyperglycemia in mice worsens outcomes and increases
the likelihood of hemorrhagic transformation after ischemic stroke.258 Future work
should explore whether the toxic effects of hyperglycemia are mediated by
neutrophils by testing whether (1) the exacerbation of stroke outcomes in young
animals by induced hyperglycemia can be reversed by neutrophil depletion and
(2) whether controlling naturally occurring hyperglycemia in aged animals
abrogates the efficacy of neutrophil depletion therapy.
Similarly, a recent paper reported that genetic hyperlipidemia (ApoE
knockout) exacerbates ischemic stroke damage in young mice, an effect that can
be reversed by neutrophil depletion.259 A complimentary study should be
performed in aged mice, with naturally occurring age-related hyperlipidemia
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controlled via diet or pharmacology, to see whether the efficacy of neutrophil
depletion is reduced in the absence of abnormal lipid levels.

6.3 Significance and Impact
The aged population is growing rapidly worldwide, driving an increase in a
wide variety of cardiovascular diseases like ischemic stroke.260, 261 First and
foremost, this work highlights the importance of examining pathological
processes and testing therapeutics in aged animal models, particularly when the
target disease occurs largely in an aged population (e.g., cerebral ischemia,
atherosclerosis, hypertension). Although clinical epidemiology has always
categorized stroke as a disease of aging, and a wealth of evidence has
suggested that age alters many aspects of stroke pathophysiology, the majority
of studies are still conducted in young, male animals.96, 262, 263 Adapting
conclusions made from studies in young animals into treatments for aged
humans is likely to significantly decrease the efficacy of clinical translation – and
may mask the potential of age-dependent candidate therapies, like the anti-Ly6G
antibody tested in Chapter 4 of this dissertation.
Aging is known to have significant and profound effects on both the
immune and cardiovascular systems.264 In particular, age-related changes in the
function of neutrophils are now believed to be a significant mediator in many agerelated diseases.265 The body of work presented in this dissertation examines the
utility of post-stroke neutrophil depletion therapy in young and aged animals and
provides new insight into the changing function of injury-induced inflammation
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throughout the lifespan. In addition, it shows that neutrophils from aged animals
exhibit altered behaviors, including an impaired clearance phenotype, greater
sensitivity to inflammatory stimulus and a higher capability for reactive species
generation.
While the studies included in this dissertation make a case for an agerelated increase in neutrophil pathogenicity after ischemic stroke, these
implications of age-induced alterations in neutrophil biology are far-reaching,
offering potential insight into the role of neutrophils in a variety of age-associated
tissue injury and inflammatory processes, including atherosclerosis, cancer and
autoimmune disease.
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